American Society of Hematology  
Annual Meeting 2014  
http://www.hematology.org/Annual-Meeting/  

(Case CCC Members indicated in **bold**)

**PRESENTATIONS/DISCUSSIONS/SESSION MODERATORS**

**Anjali Advani, MD**  
Speaker, Targeting CD19  
*Friday Satellite Symposia, Spanning Our Life Cycle: Novel Therapies, Targets, and Transplant Strategies in Acute Lymphoblastic Leukemia*
  
Friday, December 5, 2014: 12:30-4:00 pm Moscone Center, West Building 2008-2010
  
Speakers: Anjali Advani, MD, Cleveland Clinic, Cleveland, OH; David Barrett, MD, PhD, The Children’s Hospital of Philadelphia, PA; Monika Brueggemann, MD, PhD, University Hospital Schleswig-Holstein, Kiel, Germany; Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA; Mark Litowitz, MD, Mayo Clinic, Rochester, MN; Jacob Rowe, MD, Shaare Zedek Medical Center, Jerusalem, Israel

**Jennifer S Carew, PhD**  
Moderator, *Oral Poster Session 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: New Drugs II*
  
Monday, December 8, 2014: 10:30 AM-12:00 PM South Building, Gateway Ballroom 103 (Moscone Center)
  
Moderators: Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center and Jennifer S Carew, PhD, Cleveland Clinic

**Hetty Carraway, MD, MBA**  
Speaker, *Friday Satellite Symposia, Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: Past, Present, and Future*
  
Friday, December 5, 2014: 12:30-4:00 pm San Francisco Marriott Marquis Yerba Buena Ballroom, Salon 1
  
Speakers: Hetty Carraway, MD, MBA, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Torsten Haferlach, MD, PhD, Munich Leukemia Laboratory, Munich, Germany; Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; Betty Ky Hamilton, MD, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Valeria Santini, MD, University of Florence, Florence, Italy; Francesc Sole, PhD, Hospital del Mar, Barcelona, Spain

Moderator, *Oral Poster Session 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Molecular Targets and Drug Sensitivity in Myeloid Diseases*
  
Monday, December 8, 2014: 7:00 AM-8:30 AM South Building, Esplanade 301 (Moscone Center)
  
Moderators: Daniel A Pollyea, University of Colorado Cancer Center and Hetty E. Carraway, MD, MBA, Cleveland Clinic
Betty Ky Hamilton, MD
Speaker, *Friday Satellite Symposium: Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: Past, Present, and Future*
Friday, December 5, 2014: 12:30-4:00 pm San Francisco Marriott Marquis Yerba Buena Ballroom, Salon 1
Speakers: Hetty Carraway, MD, MBA, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Torsten Haferlach, MD, PhD, Munich Leukemia Laboratory, Munich, Germany; Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX; Betty Ky Hamilton, MD, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Valeria Santini, MD, University of Florence, Florence, Italy; Francesc Sole, PhD, Hospital del Mar, Barcelona, Spain

Navneet Majhail, MD, MS
Monday, December 8, 2014: 2:45 PM-4:15 PM West Building, 2006-2008 (Moscone Center)
Moderators: Navneet Majhail, MD, MS, Cleveland Clinic and Avichai Shimoni, MD, Sheba Medical Center

Keith R. McCrae, MD
Moderator, *Oral Poster Session 311. Disorders of Platelet Number or Function: Clinical Insights into TTP, ITP and HIT*
Monday, December 8, 2014: 7:00 AM-8:30 AM West Building, 2002-2004 (Moscone Center)
Moderators: Keith R. McCrae, MD, Cleveland Clinic and Nicola Cooper, MRCP, MRCPath, MD, Imperial Health Care NHS Trust, Hammersmith Hospital

Mikkael A. Sekeres, MD, MS
Speaker, *Myelodysplastic Syndromes in an Elderly Patient*
How I Treat Session: Bringing Science to Clinical Dilemmas
Saturday, December 6, 2014, 11:15 a.m. - 12:15 p.m. San Francisco Marriott Marquis (Sierra F)

Speaker, *Novel Agents for Myelodysplastic Syndromes*
Education Program Session: Current and Future Therapies for Aplastic Anemia and Myelodysplastic Syndromes
Saturday, December 6, 2014, 2:00 PM-3:30 PM Yerba Buena Ballroom Salons 7-8 (San Francisco Marriott Marquis)

Moderator, *Special-Interest Session: Special Education Session: Newly Approved Drugs*
Monday, December 8, 2014, 4:30 PM-6:00 PM North Building, Hall D (Moscone Center)
Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
Moderator: Mikkael A. Sekeres, MD, MS, Cleveland Clinic, Cleveland, OH
Speakers: Margaret V. Ragni, MD, MPH, University of Pittsburgh and Hemophilia Center of Western Pennsylvania, Pittsburgh, PA; Mitchell R. Smith, MD, PhD, Cleveland Clinic, Cleveland, OH; Steven Coutre, MD, Stanford University School of Medicine, Stanford, CA
LATE BREAKING ABSTRACTS

Tuesday, December 9

LBA-5 A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117

Late Breaking Abstracts Session
Tuesday, December 9, 2014, 7:30 AM-9:00 AM North Building, Hall D (Moscone Center)

Mikkael A. Sekeres, MD, MS1, Megan Othus, PhD2*, Alan F. List, MD3, Olatoyosi Odenike, MD4, Richard M. Stone, MD5, Steven D. Gore, MD6,7, Mark R. Litzow, MD8, Rena Buckstein, MD9, Mario r Velasco Jr., M.D.10*, Rakesh Gaur, MD11, Ehab Atallah, MD12, Eyal Attar, MD13, Frederick R. Appelbaum, MD14 and Hany P. Erba, MD, PhD15*

1Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
2Fred Hutchinson Cancer Research Center, Seattle, WA
3Malignant Hematology, Moffitt Cancer Center, Tampa, FL
4Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL
5Hematologic Oncology, Dana Farber Cancer Institute, Boston, MA
6Smilow Cancer Center, Yale School of Medicine, New Haven, CT
7Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
8Division of Hematology, Mayo Clinic, Rochester, MN
9Hematology/Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
10Cancer Care Specialists of Central Illinois, Central Illinois CCOP, Decatur, IL
11Kansas City CCOP, Kansas City, KS
12Department of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
13Hematology-Oncology, Massachusetts General Hospital, Boston, MA
14Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
15The Division of Hematology & Oncology, University of Alabama at Birmingham, Birmingham, AL

ORAL ABSTRACTS

Sunday, December 7

91 Premature Platelet Activation and Resistance to P2Y12 Inhibitors in Rasa3 Mutant Mice
Oral Abstract Session: 301. Platelet Activation and Biochemistry: Platelets in Hemostasis and Thrombosis
Sunday, December 7, 2014: 4:30 PM West Building, 3006-3008 (Moscone Center)
Wolfgang Bergmeier, PhD1, David S Paul, PhD2*, Lucia Stefanini, PhD3, Raymond F. Robledo, PhD4*, E. Ricky Chan, PhD5*, Todd M Getz, PhD6*, Raymond Piatt7*, Yacine Boulaultali, PhD7*, Mark D Adams8* and Luanne L. Peters, PhD4

1McAllister Heart Institute and Dpt. of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC
2McAllister Heart Institute, University of North Carolina, Chapel Hill, NC
3Dpt. of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC
4The Jackson Laboratory, Bar Harbor, ME
5Department of Genetics, Case Western Reserve University, Cleveland, OH
6Institute of Surgical Research, US Army, San Antonio, TX
7McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC

163 Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

Oral Abstract Session: 637. Myelodysplastic Syndromes - Clinical Studies: Clinical Studies and Disease Characterization
Sunday, December 7, 2014: 4:30 PM Yerba Buena Ballroom Salon 7 (San Francisco Marriott Marquis)

Guillermo Garcia-Manero, MD1, Pierre Fenaux, MD, PhD2, Aref Al-Kali, MD3, Maria R. Baer, MD4, Mikael A. Sekeres, MD, MS5, Gail J. Roboz, MD, PhD6, Gianluca Gaidano, MD, PhD7, Bart L Scott, MD8, Peter L. Greenberg, MD, PhD9, Uwe Platzbecker, MD10, David P. Steensma, MD11, Suman Kambhampati, MD12*, Karl-Anton Kreuzer, MD13*, Lucy A Godley, MD, PhD14, Robert Collins15, Ehab Atallah, MD16, Francois Wilhelm, MD, PhD17, Isabelle E. Wilhelm, MD17, Nozar Azamia, PhD17*, Manoj Maniar, PhD17* and Lewis R. Silverman, MD18*

1Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Service d'Hématologie Sénior, Hôpital St Louis, Université Paris 7, Paris, France
3Division of Hematology, Mayo Clinic, Rochester, MN
4Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
5Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
6Division of Hematology and Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY
7Hematology, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
8Fred Hutchinson Cancer Research Center, Seattle, WA
9Stanford University Cancer Center, Stanford University, Stanford, CA
10Medizinische Klinik und Poliklinik I, Universitätshüberklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany
11Dana Farber Cancer Institute, Boston, MA
12University of Kansas Cancer Center, Kansas City, KS
13University of Cologne, Cologne, Germany
14Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL
15University of Texas Southwestern, Dallas, TX
16Department of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
17Onconova Therapeutics, Inc, Newtown, PA
18Division of Hematology, Mount Sinai School of Medicine, New York, NY

206 Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

A Novel Mechanism of Cellular Activation Mediated By Antiphospholipid Antibody-Induced Extracellular Vesicles


Sunday, December 7, 2014: 5:15 PM West Building, 3018-3020 (Moscone Center)

Meifang Wu, M.D.1*, Suman Kundu, MBA1*, Venkaiah Betapudi, Ph.D.1* and Keith R. McCrae, M.D.2

1Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
2Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

125 DDX41 Is a Tumor Suppressor Gene Associated with Inherited and Acquired Mutations

Oral Abstract Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Genetic Mutations in Association: Novel Insights


Chantana Polprasert, MD1,2*, Isabell Schulze3*, Mikkael A. Sekeres, MD, MS1, Hideki Makishima, MD, PhD1, Bartlomiej P Przychodzen1*, Naoko Hosono, MD, PhD1, Jamal Singh, PhD5*, Richard A Padgett, PhD5*, Xiaorong Gu, PhD1*, Eckhard Jankowsky, PhD5*, Michael Clemente, MS7*, Brittney Dienes*, Sudipto Mukherjee, MD, MPH1, Utz Krug, MD3, Hans-Ulrich Klein, PhD9*, Martin Dugas, MD9*, Wolfgang E Berdel, MD3, Kenichi Yoshida, MD, PhD10*, Yuichi Shiraishi, PhD11*, Kenichi Chiba, PhD11*, Hiroko Tanaka, BA12*, Satoru Miyano, PhD12*, Seishi Ogawa, MD, PhD10, Carsten Müller-Tidow1* and Jaroslaw P. Maciejewski, MD, PhD1

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
3Department of Medicine A - Hematology, Oncology and Pneumology, University of Muenster, Muenster, Germany
Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program

Sunday, December 7, 2014: 5:30 PM North Building, 120-125 (Moscone Center)
Qi Shen1, Zijun Yidan Xu-Monette, PhD,2, Ganiraju Manyam3, Carlo Visco4, Alexander Tzankov, MD, PhD5, Xin Cao3, Lijuan Deng3, Santiago Montes-Moreno, MD, PhD6, Karen Dybkær7, April Chiu, MD8, Attilio Orazi, MD9, Youli Zu, MD, PhD10, Govind Bhagat, MD11, Kristy L. Richards, MD PhD12, Eric D. Hsi, MD13, William Cho14, Joanies HJ.M. Van Krieken, PhD, MD15, Jooryung Huh16, Maurilio Ponzoni, MD17, Andres J.M. Ferreri, MD, PhD18, John P. Famen, MD19, Michael B. Møller, MD, DMSc20, Jane N. Winter, MD21, Miguel Angel A. Piös, MD, PhD22, L. Jeffrey Medeiros, MD23 and Ken H. Young, MD, PhD23

1Hematopathology, UT MD Anderson Cancer Center, Houston, TX
2The University of Texas MD Anderson Cancer Center, Houston, TX
3UT MD Anderson Cancer Center, Houston
4Department of Hematology, Department of Cell Therapy and Hematology, Ospedale San Bortolo, Vicenza, Italy
5Institute for Pathology, University Hospital of Basel, Basel, Switzerland
6Department of Pathology, Hospital Universitario Marques de Valdecilla Fundacion IRMAV, Santander, Spain
7Department of Hematology and Aalborg Hospital Science and Innovation Center (AHSIC), Aalborg University Hospital, Aalborg, Denmark
8Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
9Department of Pathology, Weill Cornell Medical College, New York, NY
10Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, TX
11Department of Pathology & Cell Biology, Columbia University, New York, NY
12Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC
13Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH
14University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong
15Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
16Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
17Department of Pathology, San Raffaele Scientific Institute, Milano, Italy
18IRCCS San Raffaele Scientific Institute, Milano, Italy
19Gundersen Lutheran Med. Ctr., La Crosse, WI
20Gundersen Lutheran Med. Ctr., La Crosse, WI
208 Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT)


Sunday, December 7, 2014: 5:15 PM South Building, Esplanade 304-306-308 (Moscone Center)

Anita J. Kumar, MD MS1, Phyllis A. Gimotty, PhD2*, Joel Gelfand, MD MS3*, Georgina Buck4*, Jacob M. Rowe, MD5,6, Anthony H Goldstone, MD7, Adele Fielding, MB BS, PhD7, David I Marks9, Mark Litzenburger10, Elisabeth Paletta, PhD11, Hillard M. Lazarus12, Martin S. Tallman, MD13, Selina M. Luger, MD14 and Alison W. Loren, MD MS15

1Division of Hematology/Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
2Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
3Department of Dermatology, University of Pennsylvania, Philadelphia, PA
4Clinical Trial Service Unit, Oxford, United Kingdom
5Rambam Medical Center, Haifa, Israel
6Eastern Cooperative Oncology Group, Brookline, MA
7North London Cancer Network, Univ. College London Hosp., London, United Kingdom
8Haematology, University College London, London, United Kingdom
9University Hospitals NHS foundation trust, Bristol, United Kingdom
10Mayo Clinic, Rochester, MN
11Cancer Center, The North Division of Montefiore Medical Center, Bronx, NY
12Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
13Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
14Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA
15Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

209 Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial


Sunday, December 7, 2014: 5:30 PM South Building, Esplanade 304-306-308 (Moscone Center)

Nandita Khera, MD, MPH1, Navneet S. Majhail, MD, MS2, Ruta Brazauskas, PhD3, Zhiwei Wang, MS4, Mahmoud Aljurf, M.D.5, Görgün Akpek, MD, MHS6, Yoshiko Atsuta, MD, PhD7, Sara Beattie, BSc(Hons)8, Christopher N. Bredeson, MD, MSc, FRCP9, Linda J. Burns, MD10, Allen R. Chen, MD, PhD, MHS11, Jason Dehn, MPH, CHHC12, César O Freytes, MD13, Vikas Gupta, MD, FRCP, FRCPATH14, Gregory A. Hale, MD15, Yoshihiro Inamoto, MD, PhD16, Hillard M. Lazarus, MD17, Charles F. LeMaistre, MD18, Jeanne M. Palmer, MD19, Kristian Paulson, MD, FRCP19, Rachel M. Scheers, MD, MPH, FACEP21*, Amir Steinberg, MD22, David Szajcer, MD, FRCP23, John R. Wingard, MD24,
Baldeep Wirk, MD\textsuperscript{25}, William A. Wood, MD, MPH\textsuperscript{26}, Steven Joffe, MD, MPH\textsuperscript{27}, Theresa Hahn, PhD\textsuperscript{28}, Fausto R. Loberiza Jr, MD, MS\textsuperscript{29} and Stephanie J. Lee, MD, MPH\textsuperscript{16}

\textsuperscript{1}Hematology Oncology/ Blood and Marrow Transplant, Mayo Clinic Arizona, Phoenix, AZ
\textsuperscript{2}Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
\textsuperscript{3}Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI
\textsuperscript{4}Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
\textsuperscript{5}Oncology Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
\textsuperscript{6}Banner MD Anderson Cancer Center, Section of Hematology Oncology, Gilbert, AZ
\textsuperscript{7}Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan
\textsuperscript{8}University of Ottawa, Ottawa, ON, Canada
\textsuperscript{9}Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada
\textsuperscript{10}Medicine, University of Minnesota, Minneapolis, MN
\textsuperscript{11}Pediatric Oncology, Johns Hopkins University, Baltimore, MD
\textsuperscript{12}National Marrow Donor Program, Minneapolis, MN
\textsuperscript{13}Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX
\textsuperscript{14}Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
\textsuperscript{15}All Children's Hospital, St. Petersburg, FL
\textsuperscript{16}Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
\textsuperscript{17}Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
\textsuperscript{18}Hematology and Bone Marrow Transplant, Sarah Cannon, Nashville, TN
\textsuperscript{19}Mayo Clinic Arizona and Phoenix Children's Hospital, Phoenix, AZ
\textsuperscript{20}Section of Hematology and Medical Oncology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada
\textsuperscript{21}Mayo Clinic, Rochester, MN
\textsuperscript{22}Medicine, Cedars-Sinai Medical Center, Los Angeles, CA
\textsuperscript{23}Department of Medicine, University of Manitoba, Winnipeg, MB, Canada
\textsuperscript{24}UF Shands Cancer Center, University of Florida, Gainesville, FL
\textsuperscript{25}Stony Brook University, Stony Brook, NY
\textsuperscript{26}Division of Hematology/Oncology, University of North Carolina, Chapel Hill, NC
\textsuperscript{27}Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
\textsuperscript{28}Dept. of Medicine, Roswell Park Cancer Institute, Buffalo, NY
\textsuperscript{29}Internal Medicine Section of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE

168 A Novel Prognostic Model in Heavily Treated Patients with Myelodysplastic Syndromes (MDS)
Oral Abstract Session: 637. Myelodysplastic Syndromes – Clinical Studies: Clinical Studies and Disease Characterization
Sunday, December 7, 2014: 5:45 PM Yerba Buena Ballroom Salon 7 (San Francisco Marriott Marquis)

Aziz Nazha, MD\textsuperscript{1*}, David J. Seastone, DO, PhD\textsuperscript{1}, Tomas Radivoyevitch, PhD\textsuperscript{1*}, Aaron T. Gerds, MD, MS\textsuperscript{2}, Sudipto Mukherjee, MD, MPH\textsuperscript{1}, Hetty E. Camaway, MD\textsuperscript{1}, Anjali S. Advani, MD\textsuperscript{1}, Matt E. Kalaycio, MD\textsuperscript{1}, Gina Rupp\textsuperscript{1*}, Kristin Colaluca\textsuperscript{4*}, Sean Hobson, MA\textsuperscript{2*}, Jaroslaw P. Maciejewski, MD, PhD\textsuperscript{1} and Mikkael A. Sekeres, MD, MS\textsuperscript{2}

\textsuperscript{1}Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
\textsuperscript{2}Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic
\textsuperscript{3}Taussig Cancer Institute, Department of Cleveland Clinic, Cleveland, OH
\textsuperscript{4}Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
Monday, December 8

253 Chronological Analysis of Clonal Evolution in Acquired Aplastic Anemia
Oral Abstract Session: 508. Bone Marrow Failure: Molecular Mechanisms: Diagnosis and Treatment
Monday, December 8, 2014: 7:00 AM West Building, 3005-3007 (Moscone Center)
Tetsuichi Yoshizato, MD1*, Bogdan Dumitriu, MD2, Kohei Hosokawa, MD, PhD3*, Hideki Makishima, MD, PhD4, Kenichi Yoshida, MD, PhD1*, Aiko Sato, PhD1*, Yusuke Okuno, MD, PhD3*, Keisuke Kataoka, MD, PhD3*, Kenichi Chiba, PhD6*, Hiroko Tanaka, BA7*, Yuichi Shiraishi, PhD6*, Yasunobu Nagata, MD, PhD1*, Hiromichi Suzuki, MD3*, Yusuke Sato, MD1*, Yusuke Shiozawa, MD1*, Takamasa Katagiri, PhD9*, Ayana Kon, MD1*, Michael Clemente, MS4*, Masashi Sanada, MD, PhD3*, Satoru Miyano, PhD6,7*, Jaroslaw P. Maciejewski, MD, PhD4, Shinji Nakao, MD, PhD8, Neal S. Young, MD2 and Seishi Ogawa, MD, PhD1
1Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
3Cellular Transplantation Biology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan
4Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
6Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
7Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
8Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan

230 Increased Morbidity during Long Term Follow up of Survivors of Thrombotic Thrombocytopenic Purpura
Oral Abstract Session: 311. Disorders of Platelet Number or Function: Clinical Insights into TTP, ITP and HIT
Monday, December 8, 2014: 7:15 AM West Building, 2002-2004 (Moscone Center)
Shruti Chaturvedi, MD1*, Hashim Abbas, MD2* and Keith R. McCrae, M.D.3
1Division of Hematology-Oncology, Vanderbilt University, Nashville, TN
2Internal Medicine, Cleveland Clinic, Cleveland, OH
3Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

261 Downregulating Notch Signaling in KrasG12D/+ Mice Inhibits Both T-Cell Leukemia and Myeloproliferative Neoplasm in a Cell-Autonomous Manner
Oral Abstract Session: 603. Oncogenes and Tumor Suppressors: Novel roles of 'classic' oncogenes Monday, December 8, 2014: 7:30 AM South Building, Gateway Ballroom 103 (Moscone Center)
Guangyao Kong, PhD.1*, Yuan-I Chang, PhD.1*, Erik A. Ranheim, MD2, Yun Zhou1*, Yangang Liu1*, Paul Lambert, PhD.1*, Lan Zhou, MD, PhD9, Pamela Stanley, PhD.4*, Warren S. Pear, MD, PhD5 and Jing Zhang, PhD1
1McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI
322 FLT3 Mutation Increases Relapse Risk after Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia in First or Second Complete Remission: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

Oral Abstract Session: 732. Clinical Allogeneic Transplantation: Results: Comparative Transplantation Outcomes
Monday, December 8, 2014: 7:45 AM South Building, Esplanade 304-306-308 (Moscone Center)
Abhinav Deol, MD1, Salyka Sengsayadeth, MD2, Madan Jagasia, MBBS, MS3, Kwang W Ahn, PhD3, Hailin Wang, MPH4, Brenda M. Sandmaier, MD5, Steven M. Devine, MD6, Marcos de Lima, MD7, Daniel J. Weisdorf, MD8 and Wael Saber, MD, MS9
1Division of Hematology and Medical Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI
2Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
3Biostatistics, Medical College of Wisconsin- CIBMTR, Milwaukee, WI, Milwaukee, WI
4Center for International Blood & Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
5Transplantation Biology Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
6Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
7Medicine - Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH
8Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN
9Medical College of Wisconsin-CIBMTR, Milwaukee, WI

293 Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Oral Abstract Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Targeting PD1 and CD30 in Hodgkin Lymphoma and NHL
Monday, December 8, 2014: 8:00 AM West Building, 3009-3011-3022-3024 (Moscone Center)
Ann LaCasce, MD1, R. Gregory Bociek, MD2, Jeffrey Matous, MD3, Ahmed Sawas, MD4, Paolo Caimi, MD5, Stephen M. Ansell, MD, PhD6, Miguel Islas-Ohlmayer, MD7, Eric Cheung, MD8, Edward Agura, MD9, Caroline Behler, MD10, Howland Crosswell, MD11, Julie M. Vose, MD, MBA2, Neil Josephson, MD12 and Ranjana Advani, MD13
1Dana-Farber Cancer Institute, Boston, MA
2University of Nebraska Medical Center, Omaha, NE
3Colorado Blood Cancer Institute, Denver, CO
4Columbia University Medical Center, New York, NY
5Case Western Reserve University, Cleveland, OH
6Division of Hematology, Mayo Clinic, Rochester, MN
7The Jewish Hospital-Mercy Health, Cincinnati, OH
8The Oncology Institute of Hope & Innovation, Whittier, CA
9Charles A. Sammons Cancer Center, Dallas, TX
10Pacific Hematology Oncology Associates, San Francisco, CA
11St. Francis Hospital, Greenville, SC
12Seattle Genetics, Inc., Bothell, WA
373 High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900

Oral Abstract Session: 613. Acute Myeloid Leukemia: Clinical Studies: Clinical Trials and Prognosis II
Monday, December 8, 2014: 10:30 AM South Building, Esplanade 303-305-307 (Moscone Center)
Marlise R. Luskin, MD1, Ju-Whei Lee, PhD2*, Hugo F Fernandez, MD3, HILLARD M. LAZARUS4, Jacob M. Rowe, MD5, Martin S. Tallman, MD6, Elisabeth M. Paietta, PhD7, Mark Litzow8, Omar Abdel-Wahab, MD9, Jay P. Patel9*, Ross L. Levine, MD6, Zhuoxin Sun, PhD2* and Selina M. Luger, MD1
1University of Pennsylvania, Philadelphia, PA
2Dana Farber Cancer Institute, Boston, MA
3Moffitt Cancer Center, Tampa, FL
4Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
5Shaare Zedek Medical Center, Jerusalem, Israel
6Memorial Sloan Kettering Cancer Center, New York, NY
7Montefiore Medical Center, Bronx, NY
8Mayo Clinic, Rochester, MN

422 Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT)

Monday, December 8, 2014: 10:45 AM West Building, 3001-3003-3014-3016 (Moscone Center)
Andrew S. Artz, MD, MS1, Brent R. Logan, PhD2*, Xiaochun Zhu, MS2*, Görgün Akpek, MD, MHS3, Rodrigo Martino, MD, PhD4, Vikas Gupta, MD, FRCP, FRCPath5, HILLARD M. LAZARUS6, MD7, Mark R. Litzow, MD7, Alison Wakoff Loren, MD, MS8, NAVNEET S. MAJHAIL9, MD, MS10, Richard T. Maziarz, MD10, Philip L. McCarthy, MD11, Uday R. Popat, MD12, Wael Saber, MD, MS13, Stephen R. Spellman, MBS13*, Olle Ringdén, MD PhD14*, Kenneth R. Cooke, MD15 and Marcelo C. Pasquini, MD, MS16
1Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL
2Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
3Banner MD Anderson Cancer Center, Section of Hematology Oncology, Gilbert, AZ
4Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
5Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University of Toronto, Toronto,ON, Canada
6Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
7Division of Hematology, Mayo Clinic, Rochester, MN
8Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
9Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
10Oregon Health & Science University, Portland, OR
11Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY
12Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
13Center for International Blood and Marrow Transplant Research, Minneapolis, MN
14Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Stockholm, Sweden
15Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD
377 Gemtuzumab Ozogamicin (GO) in Infants with Acute Myeloid Leukemia (AML) - Combined Results from the Children’s Oncology Group (COG) Trials AAML03P1 and AAML0531
Oral Abstract Session: 613. Acute Myeloid Leukemia: Clinical Studies: Clinical Trials and Prognosis II
Monday, December 8, 2014: 11:15 AM South Building, Esplanade 303-305-307 (Moscone Center) Erin M. Guest, MD1, Richard Aplenc, MD, PhD2, Lillian Sung, MD, PhD3, Susana C. Raimondi, PhD4, Betsy A. Hirsch, PhD5*, Todd A. Alonzo, PhD6, Robert B. Gerbing, MA7*, Yi-Cheng Wang, MS8*, Samir B. Kahwash, MD9*, Amy Heerema-McKenney, MD9*, Soheil Meshinchi, MD, PhD10 and Alan S. Gamis, MD, MPH11
1Division of Hematology/Oncology, Children’s Mercy Hospitals & Clinics, Kansas City, MO
2Division of Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA
3The Hospital for Sick Children, Toronto, ON, Canada
4St. Jude Children’s Research Hospital, Memphis, TN
5University of Minnesota, Minneapolis, MN
6Keck School of Medicine, University of Southern California, Monrovia, CA
7Children’s Oncology Group, Monrovia, CA
8Nationwide Children’s Hospital, Columbus, OH
9Cleveland Clinic, Cleveland, OH
10Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
11Children’s Mercy Hospital, Kansas City, MO

395 Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma
Monday, December 8, 2014: 11:30 AM South Building, Esplanade 304-306-308 (Moscone Center) Kieron Dunleavy, MD1, Michelle Fanale, MD2, Ann LaCasce, MD3, Ariela Noy4, Paolo Caimi, MDF, Samir Parekh, MD6, John Hayslip, MD7, Deepa Jagadeesh, MD, MPH8, Raymond S Lord9*, Mary J Lechowicz, MD10*, Andrea Lucas, RN11, Louis M Staadt, MD, PhD12, Seth M. Steinberg, PhD13*, Brad Kahl, MD14, Jonathan W. Friedberg, MD15, Richard F Little, MPH, MD16, Nancy L Bartlett, MD17 and Wyndham H Wilson, MD, PhD18
1Center for Cancer Research, National Cancer Institute, Bethesda, MD
2MD Anderson Cancer Center, University of Texas, Houston, TX
3Dana-Farber Cancer Institute, Boston, MA
4Memorial Sloan-Kettering Cancer Ctr., New York, NY
5Case Western Reserve University, Cleveland, OH
6Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
7University of Kentucky, Lexington, KY
8Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
9West Michigan Cancer Center, Kalamazoo
10Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
11Kansas City CCOP, Kansas City, KS
12Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD
13Biostatistics and Data Management Section, National Cancer Institute, Bethesda, MD
14Dept of Medicine, University of Wisconsin, UW Carbone Cancer Center, Madison, WI
15James P. Wilmot Cancer Center, University of Rochester, Rochester, NY
16Cancer and Therapeutic Evaluation Program, National Cancer Institute, Bethesda, MD
17Washington University School of Medicine, St. Louis, MO
528 Aberrant Hedgehog Pathway Activity Marks Clinical MDS Progression and Accelerates Leukemic Transformation in Vivo
Oral Abstract Session: 636. Myelodysplastic Syndromes - Basic and Translational Studies: Genetic Defects in Myelodysplastic Syndromes
Monday, December 8, 2014: 4:00 PM Golden Gate Hall (San Francisco Marriott Marquis)
Lukasz P Gondek, MD, PhD1, Yiting Lim, PhD1*, Hideki Makishima, MD, PhD2*, Qijiu Wang, MA1*, Jaroslaw P. Maciejewski, MD, PhD, FACP2, Peter D Aplan, MD3, Amy E. DeZern, MD, MHS1 and William Matsui, MD1
1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
2Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
3Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD

682 Reduced Intensity Conditioning (RIC) with Rituximab Yields Excellent Outcomes after Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed Follicular Lymphoma (FL): A Phase II Multicenter Trial from the Blood and Marrow Transplant Network (BMT CTN 0701)
Oral Abstract Session: 732. Clinical Allogeneic Transplantation: Results: Haploidentical and Beyond
Monday, December 8, 2014: 5:15 PM West Building, 3005-3007 (Moscone Center)
Ginna G. Laport, M.D.1, Juan Wu, MS*2, Brent R. Logan, PhD3*, Veronika Bachanova, MD4, Chitra M. Hosing5, Timothy S. Fenske, MD6, Walter L. Longo, MD7*, Steven M. Devine, MD8, Auayporn P. Nademanee, MD, BS9, Iris Gersten, MS10*, Mary M. Horowitz, MD, MS1 and Hillard M. Lazarus, MD11 and Marcie L Riches, MD, MS12
1Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA
2On behalf of the Blood and Marrow Transplant Clinical Trials Network, Milwaukee, WI
3Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
4Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN
5Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
7Division of Hematology/Oncology, University of Wisconsin-Madison, Madison, WI
8Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
9Hematology and Hematopoietic Cell Transplantation, City of Hope Nat’l. Med. Ctr., Duarte, CA
10The EMMES Corporation, Rockville, MD
11Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
12Department of Blood and Marrow Transplantation, Clinical Division, Moffitt Cancer Center, Tampa, FL

652 Loss of Notch Receptor-Ligand Engagement Leads to Increased Hematopoietic Stem and Progenitor Cell Egress and Mobilization
Oral Abstract Session: 701. Experimental Transplantation: Basic Biology, Engraftment and Disease Activity
Monday, December 8, 2014: 5:15 PM West Building, 2001-2003-2014-2016 (Moscone Center)
Lan Zhou, MD, PhD1, Weihuan Wang, MD, PhD*2, Grant Zimmerman2, Jay Myers, MS3*, Yuanshuai Huang, MD, PhD4*, Vionnie W.C. Yu, PhD4, Dan Huang, MD, PhD5*, Shuiliang Yu, PhD6*, Yiwei Wang, MD, PhD*2, Xiaoran Huang, MD, PhD2, Jeongsup Shim, PhD3*, Minhong Yan, PhD6*, John Lowe, MD5*, Wei Xin, MD, PhD2*, Pamela Stanley, PhD, BSc7*, David T. Scadden, MD8, Alex Y Huang, MD, PhD8 and Christian W. Siebel, PhD6*
1Department of Pathology, Case Western Reserve University, Cleveland, OH
2Department of Pathology, Stanford University School of Medicine, Stanford, CA
3University at Buffalo, State University of New York, Buffalo, NY
4Columbia University, New York, NY
5University of California, Los Angeles, USA
6University of California, San Francisco, CA
623 Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML)

Oral Abstract Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation

Monday, December 8, 2014: 5:30 PM South Building, Gateway Ballroom 103 (Moscone Center)

Eytan M. Stein1, Anthony Stein2, Roland B. Walter, MD, PhD, MS3, Amir T. Fathi, MD4, Jeffrey E. Lancet, MD5, Tibor J. Kovacsics, MD6, Anjali S. Advani, MD7, Daniel J DeAngelo8, Megan M. O'Meara, MD9, Baiteng Zhao, PhD10*, Dana A. Kennedy, PharmD, BCOP10 and Harry P. Erba, MD, PhD11

1Memorial Sloan-Kettering Cancer Center, New York, NY
2City of Hope, Duarte, CA
3Fred Hutchinson Cancer Research Center, Seattle, WA
4Massachusetts General Hospital, Boston, MA
5Malignant Hematology, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL
6Huntsman Cancer Institute - University of Utah, Salt Lake City, UT
7Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
8Dana-Farber Cancer Institute, Boston, MA
9Clinical Development, Seattle Genetics, Inc., Bothell, WA
10Seattle Genetics, Inc., Bothell, WA
11University of Alabama-Birmingham, Birmingham, AL

Tuesday, December 9

796 Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403

Oral Poster Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Advances through clinical trials in ALL

Tuesday, December 9, 2014: 8:15 AM West Building, 3009-3011-3022-3024 (Moscone Center)

Wendy Stock, M.D.1, Selina M. Lugger, MD2, Anjali S. Advani, MD3, Susan Geyer, PhD4,5*, Richard C. Harvey, PhD6, Charles G. Mullighan, MBBS, MSc., MD7, Cheryl L Willman, MD8, Greg Malnassy, B.S.9*, Edy Parker10*, Kristina M Laumann, BA11*, Ben Sanford12*, Guido Marcucci, MD13, Elisabeth M. Paietta, PhD14, Michaela Liedtke, MD15, David F. Claxton, MD16, Matthew C. Foster, MD17, Frederick R. Appelbaum, MD18, Harry Erba19*, Mark R. Litzow, MD20, Martin S. Tallman, MD21, Richard M. Stone, MD21,22 and Richard A. Larson23,24

1Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL
2Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA
3Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Division of Hematology, The Ohio State University, Columbus, OH
5Alliance for Clinical Trials in Oncology Statistics and Data Center, Rochester, MN
6University of New Mexico Cancer Center, Albuquerque, NM
7Dept. of Pathology, MS #342, St. Jude Children's Rsch. Hosp., Memphis, TN
8UNM Cancer Research Facility, University of New Mexico Cancer Research and Treatment Center, Albuquerque, NM
823 In Analogy to AML, MDS Can be Sub-Classified By Ancestral Mutations


Hideki Makishima, MD, PhD1, Kenichi Yoshida, MD, PhD2*, Thomas LaFramboise, PhD3*, Bartlomiej P Przychodzen4*, Matthew Ruffalo, BS5*, Inés Gómez-Seguí, MD, PhD6, Yuichi Shiraishi, PhD7*, Masashii Sanada, MD, PhD8*, Yasunobu Nagata, MD, PhD9*, Yusuke Sato, MD10, Aiko Sato-Otsubo, PhD11, Kenichi Chiba, PhD12, Hiroko Tanaka, BA13, Tsuyoshi Nakamaki, MD14, Wolf-Karsten Hofmann, MD15, Shuichi Miyawaki, MD, PhD16, Shigeru Chiba, MD, PhD17, Satoru Miyano, PhD18, Holleh Husseinzadeh, MD19, Naoko Hosono, MD, PhD10*, Chantana Polprasert, MD10, Bhumika J Patel, MD11, Swapna Thota, MD12, Brittney Dienes*, Kathyrn M Guinta13*, Lee-Yung Shih, MD14, Yogen Saunthararajah, M.D.20, Yusuke Okuno, MD, PhD21*, Mikkael A. Sekeres, MD, MS22, Seishi Ogawa, MD, PhD23 and Jaroslaw P. Maciejewski, MD, PhD24

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
3Case Western Reserve University, Cleveland, OH
4Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
5Electrical Engineering and Computer Science, Case Western Reserve University, Cleveland, OH
6Hematology Department, University Hospital La Fe, Valencia, Spain
7Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
8Cancer Genomics Project, The University of Tokyo, Tokyo, Japan
9Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
10Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
11Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany
12Division of Hematology, Tokyo Metropolitan Otsuka Hospital, Tokyo, Japan
818 Critical Role of Stat5 in the Maintenance of Leukemic Stem Cells in Ptpn11-Associated Juvenile Myelomonocytic Leukemia
Oral Abstract Session: 635. Myeloproliferative Syndromes: Basic Science - Transcription Factors and Signaling
Tuesday, December 9, 2014: 7:45 AM West Building, 3018-3020 (Moscone Center)
Wei Liu1*, Xia Liu1*, Wen-Mei Yu1,2*, Kevin D. Bunting2 and Cheng-Kui Qu1,2
1Department of Medicine, Division of Hematology and Oncology, Center for Stem Cell and Regenerative Medicine, Case Western Reserve University, Cleveland, OH
2Department of Pediatrics, Division of Hematology/Oncology/BMT, Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta, Emory University, Atlanta, GA

777 Dose Dependent Role of Gfi1 in Human MDS and AML and Its Suitability As a Novel Target Oral Abstract Session: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Molecular Mechanisms of Myeloid Malignancy
Tuesday, December 9, 2014: 8:00 AM West Building, 2001-2003-2014-2016 (Moscone Center)
Judith Maria Hönes, M.Sc.1*, Lacramioara Botezatu, PhD1*, Lars C. Michel1*, Christian Thiede, MD2, Bert van der Reijden, Ph.D.3, Michael Heuser, MD4, Hideki Makishima, MD, PhD5, Jaroslaw P. Maciejewski, MD, PhD6, Tomas Radiovojevitch7*, Gerhard Ehninger, MD8, Ulrich Dührsen1*, Tarik Moroy, Ph.D.9 and Cyrus Khandanpour, MD1
1Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
2Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus der TU Dresden, Dresden, Germany
3Molecular Hemato-Oncology Unit, Radboud University Nijmegen Medical Centre (RUNMC), Nijmegen, Netherlands
4Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
5Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
6Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
7Case Western Reserve University, Department of Epidemiology & Biostatistics, Cleveland, OH
8Medical Clinic and Polyclinic I, University Hospital Carl Gustav Carus, 01307 Dresden, Germany
9Institut de recherches cliniques de Montréal, IRCM, Montreal, QC, Canada
784 Haploinsufficiency and Deletions of G3BP1 on Chromosome 5q Result in Induction of TP53
Oral Abstract Session: 603. Oncogenes and Tumor Suppressors: New players and potential therapeutic targets
Tuesday, December 9, 2014: 8:15 AM South Building, Esplanade 301 (Moscone Center)
Naoko Hosono, MD, PhD*, Mahfouz Reda, MD, PhD*, Bartlomiej Przychodzen*, Chantana Polprasert, MD*, Latifa Zekri, Ph.D*, Michael J. Clemente*, Jamal Tazi*, Yogen Saunthararajah, M.D.*, Mikkael A. Sekeres, MD, MS*, Jaroslaw P. Maciejewski, MD, PhD* and Hideki Makishima, MD, PhD*
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Translational hematology and oncology research, Cleveland Clinic Taussig cancer Institute, Cleveland
3Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
4Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
5Institut de Génétique Moléculaire de Montpellier UMR 5535, IFR 122, Centre National de Recherche Scientifique, Montpellier, France
6Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
7Centre National de Recherche Scientifique, Institut de Génétique Moléculaire de Montpellier (IGMM) - UMR5535, Montpellier, France
8Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Saturday, December 6

864 Strand-Specific Total RNA Sequencing Establishes the Complete Transcriptome and Alternative Splicing Repertoire in Diffuse Large B Cell Lymphoma
Poster Session: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster 1
Saturday, December 6, 2014, 5:30 PM-7:30 PM North Building, Hall E (Moscone Center)
1Department of Medicine, Division of Hematologic Malignancies, Duke University Medical Center, Durham, NC
2Duke University Institute for Genome Sciences & Policy, Durham, NC
3Division of Hematologic Malignancies, Duke University Medical Center, Durham, NC
4Duke University, Durham, NC
5University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC
6Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
7UNC School of Medicine, Hematopathology, Chapel Hill, NC
8Department of Pathology, University of Hong Kong, Hong Kong, China
9Pathology, Queen Mary Hospital, Hong Kong, Hong Kong
10Indiana University, Indianapolis, IN
11Pathology and Laboratory Medicine, Winship Cancer Institute of Emory University, Atlanta, GA
978 Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial
Poster Session 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
Saturday, December 6, 2014: 5:30 PM-7:30 PM North Building, Hall E (Moscone Center)
Anjali S. Advani, MD1, Paul Elson2*, Matt E. Kalaycio, MD3, Sudipto Mukherjee, MD, MPH4, Aaron T. Gerds, MD, MS5, Betty K. Hamilton, MD4, Sean Hobson, MA6, Arian Smith7*, Mary Lynn Rush1*, Samjhana Bogati1*, Monique Biggins8*, Eric D. Hsi, MD5, Hien K. Duong, MD6, Edward A. Copelan, MD7, Frederic J. Reu, MD1, Yogen Saunthararajah, M.D.4, Aziz Nazha, MD9, Hideki Makishima, MD, PhD7, Bartlomiej Przychodzen8*, Brittney Dienes8*, Jennifer S Carew, PhD9, Hetty E. Carraway, MD10 and Mikael A. Sekeres, MD, MS8
1Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
2Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
3Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
4Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Clinical Pathology, Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH
6Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
7Carolinas Health Care, Levine Cancer Center, Charlotte, NC
8Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
9Department of Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, OH

979 The Novel Plk Inhibitor Volasertib Overcomes Cytarabine Resistance in Acute Myeloid Leukemia
Poster Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM North Building, Hall E (Moscone Center)
Shuang Fu, MD1*, Kevin R. Kelly, MD2*, Claudia M. Espitia, MS3, Yingchun Han, MD4*, Hetty E. Carraway, MD5, Anjali S. Advani, MD5, Jaroslaw P. Maciejewski, MD, PhD6, Mikael A. Sekeres, MD, MS8, Nawrocki T. Steffan, Ph.D.3 and Jennifer S. Carew, PhD7
1Department of Hematologic Oncology & Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
2Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
3CTRC Institute for Drug Development, University of Texas Health Science Center at San Antonio, San Antonio, TX
4Department of Translational Hematology & Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland
5Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
6Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
7Department of Translational Hematology & Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

990 CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Poster Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM North Building, Hall E (Moscone Center)

**Basem M. William, MD1, Marcos de Lima, MD1, Betul Oran, MD2, Richard Champlin, MD2, Esperanza B Papadopoulos, MD4, Sergio Giralt, MD4, Bart L. Scott, MD5, Joel Hetzer, PhD6*, Xiwei Wang, PhD6*, Eric Laille, MS6*, Barry S. Skikne, MD6 and Charles Craddock, MD PhD7**

1Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
3MD Anderson Cancer Center, Houston, TX
4Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY
5Fred Hutchinson Cancer Research Center, Seattle, WA
6Celgene Corporation, Summit, NJ
7Centre for Clinical Hematology, Queen Elizabeth Hospital, Birmingham, United Kingdom

1054 Different Genomic Patterns in Patients with Primary Acute Myeloid Leukemia (AML) Compared to Secondary AML in Patients with Normal Karyotype

Poster Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM North Building, Hall E (Moscone Center)

Aziz Nazha, MD1*, David J. Seastone, DO, PhD1, Priyanka A Pophali, MD1, Tomas Radivoyevitch, PhD1, Hetty E. Camaway, MD1, Anjali S. Advani, MD1, Matt E. Kalaycio, MD1, Gina Rupp1*, Kristin Colaluca, RN1, Bartlomiej P Przychodzen1*, Hideki Makishima, MD, PhD1, Jaroslaw P. Maciejewski, MD, PhD1 and Mikkael A. Sekeres, MD, MS1

1Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
2Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
3Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
6Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
7Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
8Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
9Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

1290 Assessing the Value of Echocardiograms for Patients with Acute Myeloid Leukemia (AML) Receiving Anthracyclines

Poster Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM North Building, Hall E (Moscone Center)

David J. Seastone, DO, PhD1, Aziz Nazha, MD1*, Priyanka A Pophali, MD1, Moshe C. Omstein, MD, MA2, Hetty E. Camaway, MD1, Anjali S. Advani, MD1, Aaron T. Gerds, MD, MS1, Matt E. Kalaycio, MD1, Jaroslaw P. Maciejewski, MD, PhD1 and Mikkael A. Sekeres, MD, MS1

1Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
2Leukemia Program, Cleveland Clinic, Cleveland, OH
3Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
5Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
6Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
Bone Marrow Core Biopsy Adequacy and Variability in the United States and Canada: A Multicenter Retrospective Study

Poster Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM North Building, Hall E (Moscone Center)

Mihai Merzianu, MD¹, Richard Cheney, MD¹, Adrienne Groman, MS², George Deeb, MD¹, Gregory Wilding, PhD², Claudiu Cotta, MD³, Ramila Amre, MD⁴, Manjula Balasubramanian, MD⁵, Guilhemne Brandao, MD⁶, Russell K. Bynes, MD⁷, Sindhu Cherian, MD⁸, Elizabeth Courville, MD⁹, David Czuchlewski, MD¹⁰, Guang Fan, MD, PhD¹¹, David Grier, MD¹², Daniela Hoehn, MD, PhD¹³, Robert E Hutchison, MD¹⁴, Kedar V. Inamdar, MD, PhD¹⁵, Ridas Juskevicius, MD¹⁶, Prabhjot Kaur, MD¹⁷, John Lazarchick, MD¹⁸, Michael R Lewis, MD¹⁹, Rodney R. Miles, MD, PhD²⁰, Jerome B. Myers, MD, PhD²¹, Michel Nasr, MD²², Hina Naushad, MD²³, Horatius Olteanu, MD, PhD²⁴, Attilio Orazi, MD²⁵, Vishnu VB Reddy, MD²⁶, Valentin G Robu, MD²⁷, Gratian Salaru, MD²⁸, Julie Teruya-Feldstein, MD²⁹, Neerja Vajpayee, MD³⁰, Jeffrey Vos, MD³¹, Ling Zhang, MD³², Shangxing Zhang, MD, PhD³², Ashley V Sedelmeyer, MHA³³, Vivian Arguello, MD³⁴, Le Aye, DO³⁵, Sharon Barouk, MA³⁶, Elisa F Brega, MD, PhD³⁶, Richie Carpenter II, BS³⁷, James E. Coad, MD³⁸, Alana DiPonio, MT³⁹, Fernández García, MS, MD⁴⁰, John Grantham, BS³⁰, Snisa Ivelja, MD³⁸, Robert McKenna, MD⁴¹, Kieran Sultan, MD²¹, Matthew B Thomsen, MPH³⁸, Jie Xu, MD, PhD³⁸, LoAnn Peterson, MD³² and Vishala T. Neppalli, MD¹

¹Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY
²Department of Biostatistics & Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY
³Department of Pathology, Cleveland Clinic, Cleveland, OH
⁴Department of Pathology, McGill University Health Center, Royal Victoria Hospital, Montreal, QC, Canada
⁵Department of Pathology, Albert Einstein Medical Center, Philadelphia, PA
⁶Department of Pathology, McGill University Jewish General Hospital, Montreal, QC, Canada
⁷Department of Pathology, University of Southern California, Los Angeles, CA
⁸Department of Laboratory Medicine, University of Washington, Seattle, WA
⁹Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN
¹⁰Department of Pathology, University of New Mexico, Albuquerque, NM
¹¹Department of Pathology, Oregon Health & Science University, Portland, OR
¹²Department of Pathology, Wake Forest Baptist Medical Center, Winston-Salem, NC
¹³Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY
¹⁴Department of Pathology, SUNY Upstate Medical University, Syracuse, NY
¹⁵Department of Pathology, Henry Ford Hospital, Detroit, MI
¹⁶Department of Pathology, East Carolina University Brody School of Medicine, Greenville, NC
¹⁷Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
¹⁸Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC
¹⁹Department of Pathology and Laboratory Medicine, University of Vermont, Burlington, VT
²⁰Department of Pathology, University of Utah, Salt Lake City, UT
²¹Department of Pathology, Penrose Hospital, Colorado Springs, CO
²²Department of Pathology, University of Manitoba, Winnipeg, MB, Canada
²³Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
²⁴Department of Pathology, Medical College of Wisconsin, Milwaukee, WI
²⁵Department of Pathology, Weill Cornell Medical College, New York, NY
²⁶Department of Pathology, University of Alabama at Birmingham, Birmingham, AL
²⁷Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA
²⁸Department of Pathology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
²⁹Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY
³⁰Department of Pathology, West Virginia University, Morgantown, WV
1341 SEC23B Deficiency Results in Different Phenotypes in Humans and Mice
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Rami Khoriaty, MD1, Matthew Vasievich, MD, PhD2*, Morgan Jones, BS, MS3*, Jennifer Chase3*, Lesley Everett, BS, MPhil4, Bin Zhang, PhD5*, Ivan Maillard, MD, PhD5 and David Ginsburg, MD7
1Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI
2Cleveland Clinic, Cleveland, OH
3Life Sciences Institute, University of Michigan, Ann Arbor, MI
4Department of Human Genetics and Medical Scientist Training Program, University of Michigan, Ann Arbor, MI
5Genomic Medicine Institute, Cleveland Clinic Lerner Research Institute, Cleveland, OH
6Life Sciences Institute and Department of Internal Medicine, Division of Hematology-Oncology, University of Michigan, Ann Arbor, MI
7Departments of Internal Medicine and Human Genetics, University of Michigan and Howard Hughes Medical Institute, Ann Arbor, MI

1384 Nocturnal Hypoxemia (not sleep apnea) May Drive Reticulocytosis in Sickle Cell Disease
Poster Session: 114. Hemoglobinopathies, Excluding Thalassemia – Clinical: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Jane A. Little, MD1, Seth Rotz, MD2, Ceonne Kim, BS3*, MaryAnn O’Riordan, PhD4*, Nathan Langer, MD5*, and Colleen Lance, MD6*
1Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
2University Hospitals Case Medical Center, CWRU, Cleveland, OH
3CWRU, Cleveland, OH
4Rainbow Babies and Children, CWRU, Cleveland, OH
5Case Comprehensive Cancer Center, CWRU/University Hospitals Case Medical Center, Cleveland, OH
6Department of Medicine, CWRU, Case Medical Center University Hospitals/Pulmonary, Critical Care & Sleep Medicine, Cleveland, OH

1394 Association of Annexin A5 Resistance with Silent Infarct in Sickle Cell Disease
Poster Session: 114. Hemoglobinopathies, Excluding Thalassemia – Clinical: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Kerry A. Morrone, MD1, Xue Xiaonan, Ph.D.2*, Suzette O. Oyeku, MD, MPH3*, Jane A. Little, MD4, Catherine Driscoll, MD5, Jacob Rand, MD5 and Deepa Manwani, MD1
1Pediatrics, Children's Hospital At Montefiore, Bronx, NY
2Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY
3Pediatrics, Montefiore Medical Center, Bronx, NY
4Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
5Department of Pathology, Montefiore Medical Center, Bronx, NY
1424 Alpha-Synuclein Deficiency Is Associated with Defective Th2 Differentiation and Enhanced Regulatory T Cell Development
Poster Session: 203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Afshin Shameli, MD, PhD*, Yan Zheng, MD, PhD*, Clifford Harding, MD, PhD*, Howard Meyerson, MD* and Robert Malta, MD, PhD*
Pathology, University Hospitals Case Medical Center/ Case Western Reserve University School of Medicine, Cleveland, OH

1434 Identification of a Racially Dimorphic Variant in the Human Platelet PAR4 Thrombin Receptor Altering Platelet Function and Pharmacologic Inhibition
Poster Session: 301. Platelet Activation and Biochemistry: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Leonard C. Edelstein, PhD1, Lukas M Simon2#, Cory R Lindsay, PhD3, Xiang Kong, MD4, Raul Teruel Montoya, Ph.D.1, Benjamin E Tourdot, Ph.D14, Edward Chen, Ph.D5, Lin Ma1, Shaun R Coughlin, Ph.D1, Marvin T. Nieman, Ph.D5, Michael Holinstat, Ph.D1, Chad Shaw, Ph.D5# and Paul F Bray, MD1
1Cardena Foundation for Hematologic Research and Department of Medicine, Thomas Jefferson University, Philadelphia, PA
2Structural and Computational Biology and Molecular Biophysics, Baylor College of Medicine, Houston, TX
3Departments of Molecular and Human Genetics and Medicine, Baylor College of Medicine, Houston, TX
4Cardiovascular Research Institute, UCSF, San Francisco, CA
5Pharmacology, Case Western Reserve University, Cleveland, OH

1444 Anti-β2-GPI Antibodies Induce Von Willebrand Factor Release, Modulate Platelet Binding, and Affect VWF Proteolysis
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Christopher J. Ng, MD1, Keith R. McCrae, M.D.2, Junmei Chen, Ph.D.3, Michael Wang, MD4, Marilyn J. Manco-Johnson, MD4, Dominic W Chung, Ph.D.3#, Tara C White-Adams, Ph.D.3#, Jose A Lopez, MD7 and Jorge A Di Paola, MD8
1Department of Pediatrics, University of Colorado/Childrens Hospital Colorado, Aurora, CO
2Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
3Puget Sound Blood Center, Seattle, WA
4Pediatrics, University of Colorado, Aurora, CO
5Research, Puget Sound Blood Center, Seattle, WA
6Pediatrics, University of Colorado and Children's Hospital Colorado, Aurora, CO
7Research, Puget Sound Blood Ctr., Seattle, WA
8Dept. of Pediatrics, University of Colorado, Denver, School of Medicine, Aurora, CO

1445 The SRC Kinase Family Member Lymphocyte Specific Kinase (p56Lck) Regulates Endothelial Cell Proliferation and Survival
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Venkaiah Betapudi, Ph.D.1, Sergei M. Merkoulov, PhD1, Suman Kundu, MBA1, Ou Ji, MD2, Meifang Wu, M.D.1 and Keith R. McCrae, M.D.3
1447 NADPH Oxidase Mediates Antiphospholipid Antibody-Induced Endothelial Cell Activation
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Meifang Wu, M.D.1* and Keith R. McCrae, M.D.2
1Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
2Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

1448 The Day 1 Postoperative Platelet Count Predicts Splenectomy Response in Patients with Immune Thrombocytopenia (ITP)
Poster Session: 311. Disorders of Platelet Number or Function: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Shylaja Mani, MD1, Hashim Abbas, MD2, Akhil Parashar, MD3* and Keith R. McCrae, M.D.4
1Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH
2Internal Medicine, Cleveland Clinic, Cleveland, OH
3Internal Medicine, Cleveland Clinic, Cleveland, OH, US Virgin Islands
4Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

1531 Prolylcarboxypeptidase Is a Risk Factor for Cardiovascular Events
Poster Session: 331. Pathophysiology of Thrombosis: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Alvin H. Schmaier, MD1, Alona Merkulova, MS1*, Haley Gittleman, BA2*, Omar Alhalabi, MD1*, Evi Stavrou, MD1, Martina Veigl, Ph.D2* and Jill Bamholtz-Sloan, Ph.D2*
1Division of Hematology-Oncology, Case Western Reserve University, Cleveland, OH
2Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

1620 NF-κB Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Ling Li, MD1*, Zijun Yidan Xu-Monette, PhD2, Chi Young Ok, MD3, Alexander Tzanko4, Carlo Visco5, Nora Gisin6, Santiago Montes-Moreno, MD, PhD7*, Karen Dybkæ8, April Chiu, MD9*, Attilio Orati, MD10*, Youli Zu, MD, PhD11*, Govind Bhagat, MD12, Kristy L. Richards, MD PhD13, Eric D. Hsi, MD14, William W. L. Choi, MD, PhD15*, Joannes H.J. M. Van Krieken, PhD, MD16, Jooyung Huh17*, Maurilio Ponsoni18*, Andrea J. M. Ferreri, MD, PhD19, Michael B. Moller, MD, DMS20*, Ronald S. Go, MD21, Jane N. Winter, MD22, Miguel A. Piris, MD, PhD23*, L. Jeffrey Medeiros, MD2 and Ken H. Young, MD, PhD3
1The University of Texas MD Anderson Cancer Center, Houston
2The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
4University Hospital, Basel, Switzerland
5Department of Hematology, Ospedale San Bortolo, Vicenza, Italy
1703 Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome

Poster Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster I

Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)

Athena Kritharis, MD1, Jennifer A. Kanakry2, Laurie H. Sehn, MD MPH3, Tatyana Feldman, MD4, Aimee Kroll, MS4*, Randy D. Gascoyne, MD5, Adam M. Petrich, MD6, Jeremy S. Abramson, MD6, Francisco Hernandez-Ilizaliturri, MD6, Zeina Al-Mansour, MD7, Camille Adeimy, MD8, Jessica Hemminger, MD12, Nancy L. Bartlett, MD13, Anthony R. Mato, MD14, Paolo Caimi, MD15, Ranjana Advani, MD16, Andreas K. Klein, MD17, Izdore S. Lossos, MD17, Oliver W. Press, MD, PhD18, Sonali M. Smith, MD19, Jesus C. Fabregas, MD20, Chadi Nabhan, MD, FAC21, Timothy S. Fenske, MD22, Jonathan W. Friedberg, MD23, Julie M. Vose, MD, MBA24, Kristie A. Blum, MD25 and Andrew M. Evans, DO, MSc26

1Division of Hematology/Oncology, Tufts Medical Center, Boston, MA
2Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
3Centre for Lymphoid Cancer and Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada
4John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
5Quantitative Health Sciences, The University of Massachusetts, Worcester, MA
6Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada
7Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL
8Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA
9Departments of Immunology and Medicine, Roswell Park Cancer Institute, Buffalo, NY
1Division of Hematology/Oncology, The University of Massachusetts Medical School, Worcester, MA
2Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, IL
3Department of Pathology, Ohio State University, Columbus, OH
4Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO
5John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
6Case Western Reserve University, Cleveland, OH
7Department of Medicine, Division of Oncology, Stanford University Medical Center, Palo Alto, CA
8Department of Medicine, Division of Hematology-Oncology, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL
9Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
10Department of Medicine, Section of Hematology-Oncology, The University of Chicago, Chicago, IL
11Division of Hematology/Oncology, University of Miami, Miami, FL
12Department of Medicine, Division of Hematology/Oncology, Advocate Lutheran General Hospital, Oncology Specialists, S. C., Park Ridge, IL
13Department of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
14James P. Wilmot Cancer Center, University of Rochester, Rochester, NY
15Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE
16Division of Hematology, The Ohio State University, Columbus, OH
17800 Washington Street, Box 245, Division of Hematology/Oncology, Tufts Medical Center, Boston, MA

1710 MYC Associated and Double Protein Lymphoma: Subset Analysis of SWOG S9704
Poster Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Soham D. Puvvada, MD1, Patrick J Stiff, MD2, Michael Leblanc, PhD3*, James R. Cook, MD, PhD4,
Brad Kahl, MD5, Hongli Li, M.S.3*, Lisa M. Rimsza, M.D.6, Jonathan W. Friedberg, MD7 and Sonali M.
Smith, MD8
1University of Arizona Cancer Center, Tucson, AZ
2Cardinal Bernardin Cancer Center, Loyola University Chicago Stritch School of Medicine, Maywood, IL
3SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA
4Department of Molecular Pathology and Laboratory Medicine, Cleveland Clinic Foundation, Cleveland, OH
5Dept of Medicine, University of Wisconsin, UW Carbone Cancer Center, Madison, WI
6Department of Pathology, University of Arizona, Tucson, AZ
7James P. Wilmot Cancer Center, University of Rochester, Rochester, NY
8Department of Medicine, Section of Hematology-Oncology, The University of Chicago, Chicago, IL

1730 Efficacy of Standard Dose R-CHOP Alternating with R-HiDAC Followed By ASCT As Initial
Therapy of Mantle Cell Lymphoma: Cleveland Clinic Experience
Poster Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Danyu Sun, MD, PhD1, Brian T. Hill, MD, PhD1, Lisa Rybicki, MS*, Basel Roupail, MD19, Robert M
Dean, MD1, Deepa Jagadeesh, MD, MPH1, Aaron T. Gerds, MD, MS1, Betty K. Hamilton, MD3,
Ronald M. Sobecks, MD1, Hien K. Duong, MD1, Steven Andresen, DO1, Navneet S. Majhail, MD,
MS1, Brad Pohlman, MD1, Matt E. Kalaycio, MD5, Brian J. Bolwell, MD1 and Mitchell R. Smith, MD,
PhD1.
1834 Burden of Disease and Clinical Responses in Low and Intermediate-1 Risk Myelofibrosis Patients Treated with Ruxolitinib
Poster Session: 634. Myeloproliferative Syndromes: Clinical: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Ahmad Zarzour, MD1*, Ali Tabarroki, MD2*, Valeria Visconte, PhD2*, Rokana Taftaf, MD3*, Heesun J. Rogers, MD, PhD4*, Jing Ai, MD, PhD5, Nikolaos Papadantonakis, MD, PhD6, Alan E. Lichtin6, Yogen Saunthararajah, M.D.7, Brady L. Stein, MD MHS8 and Ramon V. Tiu, MD2
1Internal Medicine Department, Cleveland Clinic, Cleveland, OH
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Pathology, Case Western Reserve University, Cleveland, OH
4Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH
5Taussig Cancer Institute, Cleveland, OH
6Hematologic Malignancies and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
7Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
8Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL

1835 Rates of Infection in Myelofibrosis Patients Treated with Ruxolitinib
Poster Session: 634. Myeloproliferative Syndromes: Clinical: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Ahmad Zarzour, MD1*, Ali Tabarroki, MD2*, Rokana Taftaf, MD3*, Valeria Visconte, PhD2*, Jing Ai, MD, PhD5, Betty K. Hamilton, MD4, Nikolaos Papadantonakis, MD, PhD5, Alan E. Lichtin6, Leonard J. Horwitz, MD7, Anjali S. Advani, MD4, Mikkael A. Sekeres, MD, MS8 and Ramon V. Tiu, MD2
1Internal Medicine Department, Cleveland Clinic, Cleveland, OH
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Pathology, Case Western Reserve University, Cleveland, OH
4Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Taussig Cancer Institute, Cleveland, OH
6Hematologic Malignancies and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
7Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
8Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland

1893 Chronic Myelomonocytic Leukemia (CMML) Can be Categorized By Ancestral Mutational Events
Poster Session: 636. Myelodysplastic Syndromes – Basic and Translational Studies: Poster I
1897 The Impact of Clonal Architecture of IDH1 and IDH2 Mutant Cases on the Biology of Myeloid Malignancies

Poster Session: 636. Myelodysplastic Syndromes – Basic and Translational Studies: Poster I Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)

Swapna Thota, MD*, Hideki Makishima, MD, PhD*, Bartlomiej P Przychodzen*, Aaron D. Viny, MD, MS*, Bhumika J Patel, MD*, Tomas Radivoyevitch, PhD*, Mikkael A. Sekeres, MD, MS*, Hetty E. Carraway, MD, MBA*, Torsten Haferlach, Seishi Ogawa, MD, PhD and Jaroslaw P. Maciejewski, MD, PhD

1Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Hematology, Cleveland Clinic, Cleveland, OH
4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
6Japanese Red Cross, Nagoya First Hospital, Nagoya, Japan
7Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan
8Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
9Leukemia Program, Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2015 Macrophage Migration Inhibitory Factor Regulates Multiple Myeloma Bone Marrow Homing

Poster Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)

Yuhuan Zheng, PhD*, Qiang Wang, PhD*, Jianfei Qian, PhD*, Yi Li, MD*, Yong Lu, PhD*, Enguang Bi, PhD*, Mingjun Zhang, PhD*, Tianshu Li, PhD*, Maojie Yang, MS*, Yu Wu, MD, PhD*, Frederic J. Reu, MD, Zhen Cai and Qing Yi, MD, PhD

1Cancer Biology Department, Cleveland Clinic, Cleveland, OH
2Department of Haematology, West China Hospital of Sichuan University, Chengdu, China
3Lerner Research Institute, Cancer Biology Department, Cleveland Clinic, Cleveland, OH
4The Centre of Bone Marrow Transplantation, The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, China
2085 A Novel in Vitro Three Organ System Assay Identifies a Small Molecule Ubiquitin Analog with in Vivo Activity Against Myeloma
Poster Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
Sergei Vatolin, PhD1*, James G Phillips, PhD1*, Shravya Govindgari2*, Dale Grabowski1*, Yvonne Parker1*, Daniel Lindner, MD, PhD1*, Claudiu Cotta, MD, PhD3* and Frederic J. Reu, MD4
1Department of Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, OH
2Cornell University, Iteka, NY
3Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH
4Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

2134 Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010)
Poster Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I
Saturday, December 6, 2014, 5:30 PM-7:30 PM West Building, Level 1 (Moscone Center)
David S. Siegel, MD, PhD1, Jesus G. Berdeja, MD2, Jeffrey R. Infante, MD3*, Jonathan L. Kaufman, MD4, Michael (Luhua) Wang, MD5, Thomas G. Martin III, M.D.6, Ruben Niesvizky, MD7, Frederic J. Reu, MD8, Sundar Jagannath, MD9, Kanya Rajangam, MD, PhD10*, Mei Huang, MS10* and Ravi Vij, MBBS, MD11
1John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
2Sarah Cannon Research Institute, Nashville, TN
3Hematology and Medical Oncology, Emory University, Atlanta, GA
4The University of Texas M. D. Anderson Cancer Center, Houston, TX
5Department of Medicine, University of California San Francisco, San Francisco, CA
6Center for Myeloma, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY
7Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
8Hematology and Medical Oncology, Mount Sinai Hospital, New York, NY
9Onyx Pharmaceuticals, Inc., South San Francisco, CA
10Washington University School of Medicine, Saint Louis, MO

Sunday, December 7

2255 A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage
Poster Session: 612. Acute Lymphoblastic Leukemia: Clinical Studies: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Anjali S. Advani, MD1, Anthony S. Stein, MD2, Hagop M. Kantarjian, MD3, Andrei R. Shustov, MD4, Daniel J. DeAngelo, MD, PhD5*, Revathi Ananthakrishnan6*, Katherine Liau6*, Erik Vandendriess, MD6* and Wendy Stock, M.D.7
1Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2413 Fingolimod Expands Human Umbilical Cord Blood Cells (UCB) in Vitro and Improves Engraftment Rate of Human UCB in Sublethally Irradiated NOD SCID Gamma (NSG) Mice
Poster Session: 701. Experimental Transplantation: Basic Biology, Engraftment and Disease Activity: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)

Basem M. William, MD1,2, Stephen Moreton3*, Jane Reese4*, Pingfu Fu, Ph.D.5*, Julia V. Busk, Ph.D.6*, Marcos de Lima, MD7 and David N. Wald, MD, PhD8*

1Hematology and Oncology, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
2Medicine, Case Western Reserve University, Cleveland, OH
3Case Comprehensive Cancer Center, Cleveland, OH
4Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
5Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH
6Michigan State University, East Lansing, MI
7Case Comprehensive Cancer, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
8Department of Pathology, Case Western Reserve University, Cleveland, OH

2531 Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in First Remission Improves Outcome Irrespective of FLT3-ITD Allelic Burden Among Patients with Acute Myeloid Leukemia and FLT3-ITD Mutation
Poster Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)

Betul Oran, MD1, Richard E. Champlin1, Jorge E. Cortes2, Marcos de Lima, MD3, Xuemei Wang, PhD4, Hsiang-Chun Chen5*, Farhad Ravandi, MD6, Stefan O. Ciurea, MD7, Hagop M. Kantarjian, MD8 and Gautam Borthakur, MD9

1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
3Medicine - Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH
4Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
7Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

2532 Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies
Poster Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)

Betul Oran, MD1, Kai Cao, MD2*, Rima M. Saliba, Ph.D.1*, Chitra M. Hosing1, Uday R. Popat, MD1, Marcos de Lima, MD2, Yudith Carmazzi, MS3*, Amin Alousi, MD1, Partow Kebriaei1, Yago Nieto1, Gabriela Rondon, MD1, Dana Willis2*, Nina Shah1, Simrit Parmar1, Amanda Olson1*, Brandt Moore2*, Richard E. Champlin1, Katayoun Rezvani1 and Elizabeth J Shpall, MD1
2533 Improved Progression-Free Survival with Minimal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Hematological Malignancy
Poster Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Betul Oran, MD1, Saliba M. Rima, MD2*, Borje S Andersson, MD, PhD1, Marcos J de Lima, MD3, Uday R. Popat, MD1, Issa F. Khouri, MD1, Partow Kebræei1, Qaiser Bashir1, Sairah Ahmed, MD1, Elizabeth J Shpall, MD1, Richard E. Champlin1 and Gabriela Rondon, MD1
1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
3Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH

2534 Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis
Poster Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Sonali Chaudhury, MD1, Nobuko HiJiya, MD2, Zhenhuan Hu, MS3*, Rodney Sparapani, PhD4*, Matt E. Kalaycio, MD5, Edwin P. Alyea, MD6, Uday R. Popat, MD7 and Wael Saber, MD, MS8*
1Hematology-Oncology-Transplant Division, Ann & Robert H. Lurie Children’s Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL
2Ann & Robert H. Lurie Children’s Hospital/Northwestern University Feinberg School of Medicine, Chicago, IL
3Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
4Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI
5Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA
7Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
8Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX

2546 Allo- HSCT for Advanced Myelodysplastic Syndrome: MSKCC Vs MDACC
Poster Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Roni Tamari, MD1, Betul Oran, MD2, Patrick Hilden, MS3*, Esperanza B Papadopoulos, MD4, Piyanch Kongtim, MD2, Gabriela Rondon, MD2, Ann A. Jakubowski, MD, PhD4, Borje S Andersson, MD, PhD2, Sean M. Devlin, PhD5*, Sairah Ahmed, MD2, James W. Young, MD2, Uday R. Popat, MD2, Julianne Chen2, Marcos de Lima, MD5, Richard J O’Reilly, MD5*, Sergio Giraldo, MD6, Richard E. Champlin2 and Hugo Castro-Malaspina, MD4*
1Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY
2Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
2566 Association of Donor Killer Immunoglobulin-like Receptor (KIR) Genotype with Outcome after HLA-Matched Related Donor Hematopoietic Cell Transplantation for AML
Poster Session: 732. Clinical Allogeneic Transplantation: Results: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Ronald M. Sobecks, MD1, Dawn Thomas, BS2*, Aiwen Zhang, Ph.D.2*, Mostafa Mohammed Saleh, M.D.2*, Lisa Rybicki, MS2*, Melissa A Yurch1*, Hien K. Duong, MD1, Aaron Gerds, MD MS2*. Betty K. Hamilton, MD1, Robert M Dean, MD5, Brian T. Hill, MD, PhD6, Rabie Hanna, MD6, Brian J. Bolwell, MD2, Matt E. Kalaycio, MD7, Navneet S. Majhail, MD, MS8 and Medhat Askar, MD, PhD2*
1Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
2Allogen Laboratories, Cleveland Clinic, Cleveland, OH
3Taussig Cancer Institute, Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
4Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic
Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
6Pediatric Hematology/Oncology, Cleveland Clinic, Cleveland, OH
7Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

2598 Treatment Patterns Among Patients with Myelodysplastic Syndromes: Observations of 1st-Line Therapy, Discontinuation and the Need of Additional Therapies
Poster Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Sudipto Mukherjee, MD, MPH1, Christopher R. Cogle, MD2, Tanya GK Bentley, PhD3*, Michael S Broder, MD, MSHS5*, Eunice Chang, PhD3*, Moira E. Lawrence, PhD4*, Thomas J. McKeam, MD, PhD6*, Scott Megaflin4*, Rita Percy2*, Michael E. Petrone, MD, MPH4 and Gordon H Sun, MD, MS5*
1Cleveland Clinic Foundation, Cleveland, OH
2University of Florida, Gainesville, FL
3Partnership for Health Analytic Research, LLC, Beverly Hills, CA
4Onconova Therapeutics, Inc., Newtown, PA

2599 Results of the ECOG E1900 Trial in Younger Adults with AML Using an Event Free Survival Endpoint Are Concordant with Results Based on Overall Survival: Potential for a Surrogate Endpoint to Facilitate Rapid Approval of Therapies in AML
Poster Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Marlise R. Luskin, MD1, Ju-Whei Lee, PhD2*, Hugo F. Fernandez, MD3, Hilard M. Lazarus4, Jacob M. Rowe, MD5, Martin S. Tallman, MD6, Elisabeth M. Paietta, PhD7, Mark Litwok8, Omar Abdel-Wahab, MD6, Jay P. Patel2*, Ross L. Levine, MD6, Zhuoxin Sun, PhD2* and Selina M. Luger, MD1
1University of Pennsylvania, Philadelphia, PA
2Dana Farber Cancer Institute, Boston, MA
2617 Estimating Therapy-Related Myeloid Neoplasm Risks in the US
Poster Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Tomas Radivoyevitch, PhD*, Rainer K. Sachs, PhD, Robert Peter Gale, MD, PhD, DSc, FACP*, Mikael A. Sekeres, MD, MS*, Jaroslaw P. Maciejewski, MD, PhD*, Matt Kalaycio, MD* and Sudipto Mukherjee, MD, MPH*
1Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
2Department of Mathematics, University of California at Berkeley, Berkeley, CA
3Section of Hematology, Division of Experimental Medicine, Department of Medicine, Imperial College, London, United Kingdom
4Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

2620 Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy
Poster Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Mayur Narkhede, MD*, Jason Valent, MD*, Chad Cummings, MBA*, Katherine Glass, MPH, MS*, Debbie Hastings*, Beth Faiman, PhDr, CNP*, Kimberly Hamilton, CNP*, Janice Reed, RN*, Mary Ann Karam, RN*, Matt E. Kalaycio, MD, Brian J. Bolwell, MD, Mitchell R. Smith, MD, PhD, Hien K. Duong, MD*, Christy Samaras, DO* and Frederic J. Reu, MD*
1Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
2Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
3Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
4Cancer Center Research, Cleveland Clinic, Cleveland, OH
5Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

2627 Healthcare Resource Utilization and Costs Among Patients with Myelodysplastic Syndrome Who Failed 1st-Line Therapy
Poster Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Christopher R. Cogle, MD*, Sudipto Mukherjee, MD, MPH*, Tanya G. Bentley, PhD*, Michael S. Broder, MD, MS*, Eunice Chang, PhD*, Moira E. Lawrence, PhD*, Thomas J. McKeam, MD, PhD*, Scott Megaffin*, Rita Percy*, Michael E. Petrone, MD, MPH* and Gordon H. Sun, MD, MS*
1University of Florida, Gainesville, FL
2Cleveland Clinic Foundation, Cleveland, OH
3Partnership for Health Analytic Research, LLC, Beverly Hills, CA
4Onconova Therapeutics, Inc., Newtown, PA
2637 Prognostic Significance of Quality of Life in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Poster Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Betty K. Hamilton, MD1, Lisa Rybicki, MS2*, Donna M Abounader3*, Jane Dabney, LISW1*, Robert M Dean, MD1, Hien K. Duong, MD2, Brian T. Hill, MD, PhD4, Aaron Gerds, MD MS5*, Deepa Jagadeesh, MD, MPH1, Matt E. Kalaycio, MD6, Christine Lawrence, LISW1*, Linda McLellan, LISW1*, Brad Pohlmn, MD7, Ronald M. Sobecks, MD3, Brian J. Bolwell, MD4 and Navneet S. Majhail, MD, MS1
1Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
2Taussig Cancer Institute, Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
3Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
4Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
5Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

2642 Doctor-Patient Communication and Perception of Treatment Discontinuation in Myelodysplastic Syndromes (MDS) Diverge at the Time of Disease Progression
Poster Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Aaron T. Gerds, MD, MS1, Betsy Dennison, MS, RN2*, Joan Latsko, DNP, CRNP3*, Alice Houk, MS, RN4*, Stephanie Chisolm, PhD,5*, John M. Huber, MS3*, Richard M. Stone, MD6, Jaroslaw P. Maciejewski, MD, PhD7, Rami S Komrokji, MD8, Guillermo Garcia-Manero , MD9, David P. Steensma, MD10 and Mikkael A. Sekeres, MD, MS7
1Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Clarity Communications, Pompton Lakes, NJ
3Aplastic Anemia & MDS International Foundation, Rockville
4AA&MDSF, Rockville, MD
5Aplastic Anemia & MDS International Foundation, Rockville, MD
6Dana-Farber Cancer Institute, Boston, MA
7Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
8Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
9Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
10Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

2808 Thrombin Induces Apoptosis in Human and Rat Podocytes in a Protease Activated Receptor (PAR)-Dependent Manner
Poster Session: 321. Blood Coagulation and Fibrinolytic Factors: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Ruchika Sharma, MD1*, Amanda P Waller, PhD2*, Adam Guess2*, Shipra Agrawal, PhD2*, Berend Iseman2*, William E. Smoyer, MD2*, Marvin T. Nieman, PhD3 and Bryce A. Kerlin, MD2
1Division of Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH
2Center for Clinical & Translational Research, Nationwide Children's Hospital, Columbus, OH
3Clinical Chemistry and Pathobiology, Otto-von-Guericke University, Magdeburg, Germany
4Pharmacology, Case Western Reserve University, Cleveland, OH
3008 Post Transplant Lymphoproliferative Disorders (PTLD) after Solid Organ Transplant: Cleveland Clinic Experience
Poster Session 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Deepa Jagadeesh, MD, MPH1, Sharjeel Hooda, MD, MS*, Kathleen B Fenner, MS, Lisa Rybicki, MS*, Robert M Dean, MD1, Brad Pohlan, MD1, Brian T. Hill, MD, PhD1 and Mitchell R. Smith, MD, PhD1
1Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
2Internal Medicine, Cleveland Clinic, Cleveland, OH
3Taussig Cancer Institute, Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH

3065 Comparison of Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable with Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma (BCL-U) Patient Outcomes: Intensive Therapy May Not Benefit BCL-U
Poster Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Naresh Bumma, MD1*, Lisa Rybicki, MS*, Paolo Caimi, MD3, Deepa Jagadeesh, MD, MPH1, Robert M Dean, MD1, Brad Pohlan, MD1, Mitchell R. Smith, MD, PhD1 and Brian T. Hill, MD, PhD1
1Internal Medicine, Cleveland Clinic, Cleveland, OH
2Taussig Cancer Institute, Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
3Case Comprehensive Cancer Center, Cleveland, OH

3233 Hereditary Mutations Are Present As Pathogenic or Predisposition Factors in Otherwise Typical Adult MDS
Poster Session: 636. Myelodysplastic Syndromes - Basic and Translational Studies: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Bartłomiej P Przychodzen1*, Hideki Makishima, MD, PhD1, Britney Dienes3*, Tomas Radivoyevitch, PhD2, Hetty E. Caraway, MD, MBA3, Swapna Thota, MD4, Bhumika J Patel, MD1*, Mikkael A. Sekeres, MD, MS1 and Jarosław P. Maciejewski, MD, PhD5
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
3Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
5Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

3245 Gfi136N As a Novel Marker and Therapeutic Target of MDS and AML
Poster Session: 636. Myelodysplastic Syndromes - Basic and Translational Studies: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Lars C. Michel1*, Lacramioara Botezatu, PhD1*, Judith Maria Hönes, M.Sc.3*, Anna Mameth, MS*, Damien Grapton, MSc3*, Charles Vdavnais, Ph.D.3*, Ulric Gemic3*, Uwe Platzbecker, MD5, Thomas Schroeder, MD6, Rainer Haas, MD6, Bert A. van der Reijden, PhD2, Gerhard Ehniger, MD8, Jarosław P. Maciejewski, MD, PhD2, Tomas Radivoyevitch, PhD10*, Andre Görgens, PhD11*, Bemd Giebe11*, Jan Fleckhaus1*, Hideki Makishima, MD, PhD2, Tarik Moroy, PhD3, Ulrich Dührsen1* and Cyrus Khandanpour, MD1
3250 Somatic Mutations of the Breast Cancer Amplified Sequence-1 (BCAS1), a Novel Leukemogenic Driver in Myelodysplastic Syndromes with Del(20q)
Poster Session: 636. Myelodysplastic Syndromes – Basic and Translational Studies: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Valeria Visconte, PhD1*, Ali Tabarroki, MD1*, John Barnard2*, Li Zhang3*, Juraj Bodo, PhD4*, Reda Mahfouz, MD1*, Betty K. Hamilton, MD5, Mikkael Sekeres5*, Anjali S. Advani, MD5, Matt E. Kalaycio, MD5, Yogen Saunthararajah, M.D.3, Velizar Shivarov, M.D., Ph.D.6, Shashirekha Shetty, PhD4, Heesun J. Rogers, MD, PhD* and Ramon V. Tiu, MD1
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
3Division of Hematology and Medical Oncology Department of Medicine UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
4Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH
5Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Hematopathology and Immunology, National Hematology Hospital, Sofia, Bulgaria

3251 An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion
Poster Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Rami S Komrokji, MD1, Guillermo Garcia-Manero, MD2, Lionel Ades, MD, Ph.D.3, Abderrahmane Laadem, MD4, Bond Vo, PharmD5, Thomas Prebet, MD, Ph.D.5, Aspasia Stamatioula, MD5, Thomas Boyd, MD5*, Jacques Delaunay, MD5*, David P. Steensma, MD5, Mikkael A. Sekeres, MD, MS, Odile Beyne-Rauzy, MD, PhD*, Jun Zou, MS*, Kenneth Attie, MD*, Matthew L. Sherman, MD, Pierre Fenaux, MD, PhD* and Alan F. List, MD
3259 Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs)

Poster Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Lewis R. Silverman, MD1*, Pierre Fenaux, MD, PhD2, Aref Al-Kali, MD3, Maria R. Baer, MD4, Mikkael A. Sekeres, MD, MS5, Gail J. Roboz, MD6, Gianluca Gaidano, MD, PhD7, Bart L. Scott, MD8, Peter L. Greenberg, MD, PhD9, Uwe Platzbecker, MD10, David P. Steensma, MD11, Suman Kambhampati, MD12*, Karl-Anton Kreuzer, MD13*, Lucy A Godley, MD, PhD14, Robert Collins15, Ehab Atallah, MD16, Shyamala C. Navada, MD1, Francois Wilhelm, MD, PhD17, Nozar Azamia, PhD17*, and Guillermo Garcia-Manero, MD18

1Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Hôpital St Louis, Paris, France
4Celgene Corporation, Summit, NJ
5Institut Paoli Calmettes, Marseille, France
6Centre Henri Becquerel, Rouen, France
7North Star Lodge Cancer Center, Yakima, WA
8CHU de Nantes – Hôtel Dieu, Nantes, France
9Dana Farber Cancer Institute, Boston, MA
10Leukemia Program, Cleveland Clinic, Cleveland, OH
11Centre Hospitalier Universitaire Purpan Pavilion de Médecines, Toulouse, France
12Acceleron Pharma, Cambridge, MA
13Service d’Hématologie Séniors, Hôpital St Louis, Université Paris 7, Paris, France
14Malignant Hematology, Moffitt Cancer Center, Tampa, FL

3273 Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA)

Poster Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Aziz Nazha, MD1*, **Mikkael A. Sekeres, MD, MS1**, Guillermo Garcia-Manero, MD2, John Bamard3*, Najla H Al Ali4*, Gail J. Roboz, MD5, David P. Steensma, MD6, Amy E. DeZem, MD, MHS7, Cassie Zimmerman, MA8*, Elias J. abbour, MD5, Molly D. Greenberg, B.S.9*, Sangmin Lee, M.D.10*, Alan F List, MD4, Hagop M. Kantarjian, MD11, **Jaroslaw P. Maciejewski, MD, PhD1** and Rami S Komrokji, MD12

1Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
2Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
3Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
4Malignant Hematology, Moffitt Cancer Center, Tampa, FL
5Division of Hematology and Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY
6Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
7Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
8Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
9Department of Medicine, Weill Cornell Medical College, New York, NY
10Weill Comell/New York Presbyterian Hospital, New York, NY
11Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
12Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

**3274 Differences in Genomic Patterns and Clinical Outcomes Between African-American and White Patients with Myelodysplastic Syndromes (MDS)**

Poster Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Aziz Nazha, MD1*, Tomas Radivoyevitch, PhD1*, David J. Seastone, DO, PhD1, Brittney Dienes1*, Bartlomiej P Przychodzen1*, Jennifer S. Carew, Ph.D.1, Sudipto Mukherjee, MD, MPH1, Hetty E. Carraway, MD1, Anjali S. Advani, MD1, Matt E. Kalaycio, MD3, Sean Hobson, MA2*, Gina Rupp1*, Kristin Colaluca, RN2*, Aaron T. Gerds, MD, MS2, Jaroslaw P. Maciejewski, MD, PhD1 and Mikkael A. Sekeres, MD, MS1

1Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
2Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH

**3275 The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure**

Poster Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Aziz Nazha, MD1*, Rami S Komrokji, MD2, Guillermo Garcia-Manero, MD3, John Bamard4*, Cassie Zimmerman, MA5*, Ali Al Najla6*, Gail J. Roboz, MD7, David P. Steensma, MD6, Amy E. DeZem, MD, MHS8, Elias J. abbour, MD9, Sangmin Lee, M.D.10*, Molly D. Greenberg, B.S.11*, Alan F List, MD12, Hagop M. Kantarjian, MD10, Jaroslaw P. Maciejewski, MD, PhD1 and Mikkael A. Sekeres, MD, MS1

1Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
2Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
3Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
4Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH
5Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
6Department of Medicine, Weill Cornell Medical College, New York, NY
7Department of Medicine, Weill Cornell Medical College, New York, NY
8Department of Medicine, Weill Cornell Medical College, New York, NY
9Department of Medicine, Weill Cornell Medical College, New York, NY
10Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
11Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
12Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
6Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
7Division of Hematology and Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, New York, NY
8Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
9 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
10Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
11Weill Cornell/New York Presbyterian Hospital, New York, NY
12Department of Medicine, Weill Cornell Medical College, New York, NY
13Malignant Hematology, Moffitt Cancer Center, Tampa, FL

3276 Treatment with Romiplostim, a Thrombopoietin-Receptor Agonist, in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Updated Follow-up Results for Acute Myeloid Leukemia (AML) and Survival from a Randomized, Double-Blind, Placebo (PBO)-Controlled Study
Poster Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II
Sunday, December 7, 2014, 4:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Hagop M. Kantarjian1, Ghulam Mufti2*, Pierre Fenaux3*, Mikkael Sekeres4*, Jeffrey Szer5*, Uwe Platzecker6*, Andrea Kuendgen, MD7*, Gianluca Gaidano8*, Wieslaw Wiktor-Jedrzejczak9*, Amelia Orejudo10*, Angela Lopez10* and Aristoteles Giagounidis12*
1 The University of Texas MD Anderson Cancer Center, Houston, TX
2 Kings College London, London, United Kingdom
3 Service d’hématologie clinique, Hopital Avicenne Universite Paris XIII, Bobigny, France
4 Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
5 Clinical Haematology, Royal Melbourne Hospital, Melbourne, Australia
6 University Hospital Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany
7 Department of Hematology, Oncology, and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
8 Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
9 Medical University of Warsaw, Warsaw, Poland
10 Amgen Inc., Morganville, NJ
11 Amgen Inc., Thousand Oaks, CA
12 Marien Hospital Düsseldorf, Düsseldorf, Germany

3380 Chemokines CCL14 and CCL3 Facilitate Monocytes/Macrophage Infiltration in Multiple Myeloma Bone Marrow
Poster Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Yi Li, M.Med1*, Yuhuan Zheng, PhD2,3*, Li Yang, M.Med1*, Qiang Wang, PhD2*, Enguang Bi, PhD2*, Tianshu Li, PhD2*, Yong Lu, PhD2*, Jianfei Qian, PhD2*, Mingjun Zhang, PhD2*, Maojie Yang, MS2*, Qing Yi, MD, PhD2 and Zhen Cai, MD, PhD1*
1 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qing Chun Rd., Hangzhou, 310003, China, Hangzhou, China
2 Lerner Research Institute, Cancer Biology Department, Cleveland Clinic, Cleveland, OH
3 Hematology Department, West China School of Medicine, Sichuan University, Chengdu, China

3507 Effects of Monoclonal Gammopathy of Undetermined Significance (MGUS) on Outcomes after Solid Organ Transplant
Program: Oral and Poster Abstracts
Session: 901. Health Services and Outcomes Research – Non-Malignant Conditions: Poster II
Sunday, December 7, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Teresa E Goebel, D.O.\textsuperscript{1}, Nicholas K Schiltz, Ph.D.\textsuperscript{2*}, Aiswarya Chandran Pillai, M.D./M.S.\textsuperscript{2*}, \textit{Paolo Caimi, MD}\textsuperscript{3,4}, \textit{Sian M Koroukian, Ph.D.}\textsuperscript{5*}, Kenneth J Woodside, M.D.\textsuperscript{6*} and \textit{Erica L Campagnaro, MD}\textsuperscript{7}
\textsuperscript{1}Medicine, Division of Hematology and Oncology, University Hospitals Case Medical Center, Cleveland, OH
\textsuperscript{2}Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH
\textsuperscript{3}Case Western Reserve University, Cleveland, OH
\textsuperscript{4}Case Comprehensive Cancer Center, Cleveland, OH
\textsuperscript{5}Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH
\textsuperscript{6}Surgery, Division of Transplant and Hepatobiliary Surgery, University Hospitals Case Medical Center, Cleveland, OH
\textsuperscript{7}Medicine, Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

\textbf{Monday, December 8}

\textit{3567 GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition}
Poster Session: 603, Oncogenes and Tumor Suppressors: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Akinori Yoda, PhD\textsuperscript{1*}, Guillaume Adelmant, PhD\textsuperscript{2*}, Jerome Tamburini, MD, PhD\textsuperscript{3*}, Bjoern Chapuy, MD, PhD\textsuperscript{4}, Nobuaki Shindoh, PhD\textsuperscript{5*}, Yuka Yoda, MPH\textsuperscript{6*}, Oliver Weigert, MD\textsuperscript{4,8}, Nadja Kopp, MA\textsuperscript{4*}, Shuo-Chieh Wu\textsuperscript{4*}, Sunhee S. Kim\textsuperscript{1*}, Huiyun Li\textsuperscript{4*}, Trevor Tivey\textsuperscript{1*}, Amanda L Christie\textsuperscript{4*}, Kutlu G Elpek\textsuperscript{4*}, Joseph Card\textsuperscript{10*}, Kira Gritsman, MD, PhD\textsuperscript{11}, Jason Gotlib, MD, MS\textsuperscript{12}, Michael W. Deininger\textsuperscript{13*}, Hideki Makishima, MD, PhD\textsuperscript{14}, Shannon Turley, PhD\textsuperscript{15}, Nathalie Javidi-Shariff\textsuperscript{15*}, Jaroslaw P. Maciejewski, MD, PhD\textsuperscript{16}, Scott J Rodig, MD, PhD\textsuperscript{17}, Jeffrey W. Tyner\textsuperscript{18}, Jarrod A Marto, PhD\textsuperscript{19*}, David M. Weinstock, MD\textsuperscript{4} and Andrew A. Lane, MD, PhD\textsuperscript{1}
\textsuperscript{1}Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
\textsuperscript{2}Cancer Biology, Dana-Farber Cancer Institute, Boston
\textsuperscript{3}Institut Cochin, Département Développement, Reproduction, Cancer, Université Paris \textsuperscript{5}, Paris, France
\textsuperscript{4}Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Japan
\textsuperscript{5}Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
\textsuperscript{6}Dana-Farber Cancer Institute, Boston
\textsuperscript{7}Department of Internal Medicine III, University Hospital, Munich, Germany
\textsuperscript{8}Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, MA
\textsuperscript{9}Cancer Biology and Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA
\textsuperscript{10}Cancer Biology, Dana-Farber Cancer Institute - Harvard Medical School, Boston, MA
\textsuperscript{11}Stanford University School of Medicine, Stanford, CA
\textsuperscript{12}Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
\textsuperscript{13}Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
\textsuperscript{14}Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR
\textsuperscript{15}Leukemia Program, Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
\textsuperscript{16}Department of Pathology, Brigham and Women's Hospital, Boston, MA
\textsuperscript{17}Department of Cell and Developmental Biology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR
\textsuperscript{18}Cancer Biology, Dana-Farber Cancer Institute, Boston, MA
Impact and Function of Somatic PHF6 Mutations in Myeloid Neoplasms

Poster Session: 603. Oncogenes and Tumor Suppressors: Poster III

Monday, December 8, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)

Brittney Dienes*, Bartłomiej P Przychodzen*, Michael Clemente, MS*, Wenyi Shen, MD†, 3*, Chantana Polprasert, MD‡, Naoko Hosono, MD, PhD§, Satoru Miyano, PhD¶, Yuichi Shiraishi, PhD∥, Kenichi Yoshida, M.D.¶, Seishi Ogawa, MD, PhD¶, 7, Mikkael A. Sekeres, MD, MS, Yogen Saunthararajah, M.D.¶, Jarosław P. Maciejewski, MD, PhD§, 9 and Hideki Makishima, MD, PhD§

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Department of Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
4Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
5Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
6Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
7Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
8Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
9Leukemia Program, Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Activity of ABT-199 and Acquired Resistance in Follicular Lymphoma Cells

Poster Session: 605. Molecular Pharmacology, Drug Resistance - Lymphoid and Other Diseases: Poster III

Monday, December 8, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)

Juraj Bodo, PhD¹*, Xiaoxian Zhao, PhD¹*, Mitchell R. Smith, MD, PhD² and Eric D. Hsi, MD¹

¹Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH
²Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

A Randomized Phase II Trial of Three Novel Regimens for Relapsed/Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906

Poster Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III

Monday, December 8, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)

Mark R. Litzow, MD¹, Xin Victoria Wang, PhD²*, Martin P. Carroll, MD³, Judith E. Karp, MD⁴, Rhett Ketterling, MD⁵*, Scott H. Kaufmann, MD, PhD⁶, Hillard M. Lazarus⁶, Selina M. Luger, MD⁷, Elisabeth M. Paietta, PhD⁸, Jacob M. Rowe, MD⁹, Jessica K Altman¹⁰, Keith W Pratz, MD¹², E. Randolph Broun, MD¹³ and Martin S. Tallman, MD¹⁴

¹Division of Hematology, Mayo Clinic, Rochester, MN
²Dana Farber Cancer Institute, Boston, MA
³Division of Hematology/Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
⁴Department of Oncology, Division of Hematological Malignancies, Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, MD
⁵Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
⁶Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
3756 KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, Is Active and Well Tolerated in a Phase I/II Study of Advanced Hematologic Malignancies
Poster Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Ronan T Swords, MD, PhD, FRCPI, FRCPath1*, Andrew H Wei, MBBS, PhD2, Simon Durrant, MBBS, MRCs, LRCP, FRCP, FRCPa3, Anjali S. Advani, MD4, Mark S Hertzberg, MBBS PhD FRACP FRCPA5, Ian D Lewis, MBBS, PhD6, Peter L. Greenberg, MD, PhD7, Jorge Cortes, MD8, Geoff T Yarranton, PhD9, Jackie M. Walling, MBChB, PhD10 and Jeffrey E. Lancet, MD11
1Department of Medicine, Division of Hematology-Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center, Miami, FL
2Department of Clinical Haematology, The Alfred Hospital and Monash University, Melbourne, Australia
3The Royal Brisbane and Women's Hospital, Brisbane, Australia
4Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
5Department of Haematology, Westmead Hospital, Westmead, Australia
6The Royal Adelaide Hospital, Adelaide, Australia
7Hematology, Stanford University Cancer Institute, Stanford, CA
8Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
9KaloBios Pharmaceuticals, Inc., South San Francisco, CA
10KaloBios Pharmaceuticals, Inc, South San Francisco
11Malignant Hematology, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL

3766 Inhibition of p97 with the First-in-Class Small Molecule CB-5083: A Novel Strategy for Acute Myeloid Leukemia Therapy
Poster Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)
Rita Tohme, BS1, Ronan Le Moigne, PhD2*, Bartlomiej P Przychodzen3*, Yingchun Han, MD4*, Mark Rolfe, PhD5, Hetty E. Carraway, MD6, Stevan Djakovic, PhD7, Dan Anderson, PhD8, David Wustrow, PhD9, Han-Jie Zhou, PhD9, Steve Wong9, Kevin R. Kelly, MD8*, Yogen Saunthararajah, M.D.9, Anjali S. Advani, MD10, Jaroslaw P. Maciejewski, MD, PhD11, Mikkael A. Sekeres, MD, MS12, Steffan T. Nawrocki, PhD13 and Jennifer S. Carew, PhD1
1Department of Translational Hematology & Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
2Cleave Biosciences, Burlingame, CA
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Department of Translational Hematology & Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland
5Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
6Cleave Biosciences, Burlingame
7Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
3811 Intra-Osseous Co-Transplantation of CD34-Selected Umbilical Cord Blood and Mesenchymal Stromal Cells

Poster Session: 701. Experimental Transplantation: Basic Biology, Engraftment and Disease Activity: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)

Leland Metheny III, MD1,2, Marcos de Lima, MD3,4, Stanton Gerson, MD2,5, Saada Eid, BS6* and Alex Yee-Chen Huang, MD, PhD7,7*

1Medicine, Case Western Reserve University, Cleveland, OH
2University Hospitals Seidman Cancer Center, Cleveland, OH
3Case Western Reserve University, Cleveland, OH
4Medicine - Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH
5Medicine, Case Western Reserve University, Cleveland, OH
6Pediatrics, Case Western Reserve University, Cleveland, OH
7Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH

3836 Novel Approach for NK Cell Therapy for Cancer

Poster Session: 703. Adoptive Immunotherapy: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)

Reshmi Parameswaran, PhD1*, David N. Wald, MD, PhD2,3*, Marcos De Lima, MD4, Dean A. Lee, MD, PhD5 and Stephen Moreton6*

1Case Western Reserve University, Cleveland, OH
2Department of Pathology, Case Western Reserve University, Cleveland, OH
3Pathology, University Hospitals Case Medical Center, Cleveland, OH
4Medicine - Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH
5Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
6Case Comprehensive Cancer Center, Cleveland, OH

3854 Brentuximab Vedotin (BV) Does Not Impair Autologous Peripheral Blood Stem Cell Mobilization and Collection in Refractory/Relapsed CD30+ Lymphoma Patients Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplant (HDC-ASCT)

Poster Session: 711. Cell Collection and Processing: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM North Building, Hall E (Moscone Center)

Manuel Afable, BSN, MD1*, Paolo F. Caimi, MD2, Chitra Hosing3, Marcos de Lima, MD4, Issa F. Khouri, MD4, Basem M. William, MD5, Yago Nieto, MD, PhD6, Brenda W. Cooper, MD7*, Paolo Anderlini, MD3, Erica L. Campagnaro, MD3, Stanton L. Gerson2, Hillard M. Lazarus, MD7, Richard E. Champlin8 and Uday R. Popat, MD8

1Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH
2Medicine - Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH
3Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, Houston, TX
4Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX
5Hematology and Oncology, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
4009 Long Term Outcomes of Warm and Cold Antibody-Mediated Autoimmune Hemolytic Anemia Treated with Rituximab from a 13 Year Retrospective Cohort
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Shruti Chaturvedi1*, Amy Chang, MD2* and Keith R. McCrae, M.D.3
1Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
2Department of Internal Medicine, University of Michigan, Ann Arbor, MI
3Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

4053 SCD-Biochip: A Functional Assay for Red Cell Adhesion in Sickle Cell Disease
Poster Session: 113. Hemoglobinopathies, Excluding Thalassemia – Basic and Translational Science: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Jane A Little, MD1, Yunus Alapan, MSc2*, Kayla E Gray, BA3* and Umut A Gurkan, PhD2*
1Department of Medicine, Case Western Reserve University, Cleveland, OH
2Department of Mechanical & Aerospace Engineering, Case Western Reserve University, Cleveland, OH
3Department of Medicine, Case Western Reserve University, Cleveland, OH

4074 Identifying Renal Microstructural and Blood Flow Changes in Sickle Cell Disease Using Quantitative MRI Techniques
Poster Session: 114. Hemoglobinopathies, Excluding Thalassemia – Clinical: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Connie M. Piccone, MD1, Lan Lu, PhD2*, Shannon Donnola2*, Katherine Dell, MD3*, Jane A. Little, MD4 and Chris Flask, PhD2*
1Pediatric Hematology/Oncology, Rainbow Babies and Children's Hospital, Cleveland, OH
2Dept of Radiology, University Hospitals Case Medical Center, Cleveland, OH
3Dept of Pediatrics, Cleveland Clinic Foundation, Cleveland, OH
4Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH

4166 Analysis of Protease Activated Receptor 4 (PAR4) By Histidine Hydrogen Deuterium Exchange
Poster Session: 301. Platelet Activation and Biochemistry: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Marvin T. Nieman, PhD1, Maria de la Fuente1* and Masaru Miyagi, PhD2*
1Pharmacology, Case Western Reserve University, Cleveland, OH
2Case Western Reserve University, Cleveland, OH

4243 Endogenous Thrombin Potential is Directly Correlated with Proteinuria Severity in Both Nephrotic Syndrome Patients and an Animal Model of Nephrotic Syndrome
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Amanda P Waller, PhD1*, Marvin T. Nieman, PhD2, William E. Smoyer, MD1* and Bryce A. Kerlin, MD1
1Center for Clinical & Translational Research, Nationwide Children's Hospital, Columbus, OH
2Pharmacology, Case Western Reserve University, Cleveland, OH

4249 Risk of Arterial and Venous Thrombosis in Patients with “Indeterminate” Lupus Anticoagulant Testing
Poster Session: 331. Pathophysiology of Thrombosis: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Suchitra Sundaram, MD1, Natasha Catherine Edwin, MD1, Heesun J. Rogers, MD, PhD2*, Bernard J. Silver, MD3 and Keith R. McCrae, M.D.4
1Cleveland Clinic, Cleveland, OH
2Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH
3Department of Hematologic Oncology and Blood disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

4254 Therapy with Bevacizumab Is Associated with Reduced Expression of KLF2 in Peripheral Blood Mononuclear Cells: A Potential Prothrombotic Mechanism
Poster Session: 331. Pathophysiology of Thrombosis: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Suman Kundu, MBA1*, Micheal Mawhorter, BS2*, Sergei M. Merkoulov, PhD1*, Keith R. McCrae, M.D.2 and Alok A. Khorana, MD, on behalf of the CATCH Investigators3
1Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
2Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
3Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

4255 Post Operative Thrombosis Among Patients Testing Indeterminate for Lupus Anticoagulant
Poster Session: 331. Pathophysiology of Thrombosis: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Natasha Catherine Edwin, MD1, Suchitra Sundaram, MD1, Keith R. McCrae, M.D.2, Heesun J. Rogers, MD, PhD3* and Bernard J. Silver, MD4
1Cleveland Clinic, Cleveland, OH
2Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH
3Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH
4Department of Hematologic Oncology and Blood disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4569 Fasudil, a Rho-Associated Protein Kinase (ROCK) Inhibitor, Decreases Disease Burden in a Cbl/Cbl-b Deficiency-Driven Murine Model for Myeloproliferative Disorders
Poster Session: 635. Myeloproliferative Syndromes: Basic Science: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Basem M. William, MD1,2,3, Dan Feng4*, Wei An4*, Scott Nadeau4*, Bhopal Mohapatra4*, Matt Storc4* and Hamid Band, MD, PhD4
1Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
2Hematology and Oncology, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
3Medicine, Case Western Reserve University, Cleveland, OH
4587 Nitric Oxide As a Mediator of Bone Marrow Fibrosis in Patients with Myelofibrosis
Poster Session: 635. Myeloproliferative Syndromes: Basic Science: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Ali Tabarroki, MD1*, Daniel Lindner, MD, PhD1*, Valeria Visconte, PhD1*, Nikolaos Papandantonakis1*, Jing Ai, MD, PhD1, Mikkael A. Sekeres, MD, MS2, Anjali S. Advani, MD2, Matt E. Kalaycio, MD2, Tracy Cinali, RN2*, Kristin Colaluca, RN2*, Gina Rupp3*, John Desamito2*, Heesun J. Rogers, MD, PhD4* and Ramon V. Tiu, MD1
1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
4Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH

4591 Exome Sequencing of Familial MDS Reveals Novel Mutations and High Rates of False Positive Mutations in MLL3 Due to Pseudogene Effects
Poster Session: 635. Myeloproliferative Syndromes: Basic Science: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Timothy Geoffrey Bowler, PhD, MBBS1*, Matthias Bartenstein, MD2, Kerry A. Morrone, MD3, Mersedeh Rohanizadegan, MD4*, Rachel M. Kessel, MD5*, Lauren Hooda6*, Ishan Datt6*, Orsolya Giricz, PhD7*, Tushar D. Bhagat, PhD7*, Bartlomiej P Przychodzen8*, Smit Parmar9, Jonathan B. Gill, MD10, Yiting Yu, PhD7*, Jaroslaw P. Maciejewski, MD, PhD11, Ulrich Steidl, MD PhD12 and Amit Verma, MD13
1Montefiore Medical Center, Bronx, NY
2Department of Medicine-Oncology, Albert Einstein College of Medicine, Bronx, NY
3Pediatrics, Children's Hospital At Montefiore, Bronx, NY
4Jacobi Medical Center, New York
5Children's Hospital At Montefiore, Bronx, NY
6Albert Einstein College of Medicine, New York
7Department of Developmental & Molecular Biology, Albert Einstein College of Medicine, Bronx, NY
8Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
9Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
10Children's Hospital At Montefiore, Bronx, NY
11Leukemia Program, Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
12Departments of Cell Biology and Medicine (Oncology), Albert Einstein College of Medicine, New York, NY
13Department of Medicine-Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

4600 Somatic Mutations in the Wiskott-Aldrich Syndrome Protein Family Member 3 (WASF3) Are Associated with Poor Prognosis in Myeloid Malignancies
Poster Session: 636. Myelodysplastic Syndromes – Basic and Translational Studies: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Valeria Visconte, PhD1*, Ali Tabarroki, MD1*, Li Zhang2*, Aaron T. Gerds, MD, MS3, Heesun J. Rogers, MD, PhD4*, Velizar Shivarov, M.D., Ph.D.5, John Bamard6* and Ramon V. Tiu, MD1
4603 Distinct Pattern of Genomic Changes Associated with Hypoplastic Compared to Hyper/Normoblastic Myelodysplastic Syndromes (MDS)

Poster Session: 636. Myelodysplastic Syndromes – Basic and Translational Studies: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Aziz Nazha, MD1, David J. Seastone, DO, PhD1, Tomas Radivojevitch, PhD1*, Brittney Dienest1*, Bartlomiej Przychodzen1*, Sean Hobson, MA2*, Sudipto Mukherjee, MD, MPH2, Hetty E. Carraway, MD1, Jennifer S. Carew, PhD2, Anjali S. Advani, MD1, Aaron T. Gerds, MD, MS2, Hideki Makishima, MD, PhD1, Mikkael A. Sekeres, MD, MS2 and Jaroslaw P. Maciejewski, MD, PhD1
1Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
2Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
3Department of Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, OH

4605 Analysis of Clonal Hierarchy Shows That Other Ancestral Events May Precede Evolution of Del(5q) in Myeloid Neoplasms

Poster Session: 636. Myelodysplastic Syndromes – Basic and Translational Studies: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Naoko Hosono, MD, PhD1,2*, Hideki Makishima, MD, PhD3, Bartlomiej P Przychodzen4*, Thomas LaFramboise, PhD5*, Chantana Polprasert, MD3,6*, Michael J. Clemente7*, Jacqueline Boulwood, PhD8, Mikkael A. Sekeres, MD, MS9 and Jaroslav P. Maciejewski, MD, PhD10
1Translational Hematology and Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
2First Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
3Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
4Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH
5Case Western Reserve University, Cleveland, OH
6Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
7Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
8LRF Molecular Haematology Unit, NDCLS, John Radcliffe Hospital, Oxford, United Kingdom
9Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
10Leukemia Program, Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

4610 Multiple Mechanisms Leading to ARID2 defects in Myeloid Neoplasms

Poster Session: 636. Myelodysplastic Syndromes – Basic and Translational Studies: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Paolo Caimi, MD1, Brenda Cooper, MD1, Basem M. William, MD2, Erica L Campagnaro, MD1, Richard J. Creger, Pharm D1*, Manuel Afable, BSN, MD3*, Yan Xu, PhD4,5*, John Pink, PhD4,5*, Afshin Dowlati4*, Hillard M. Lazarus, MD2, Marcos de Lima, MD4 and Stanton L. Gerson1
1Medicine - Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH
2Hematology and Oncology, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
3University Hospitals Seidman Cancer Center, Cleveland, OH
4Translational Research & Pharmacology Core Facility, Case Comprehensive Cancer Center, Cleveland, OH
5Department of Chemistry, Cleveland State University, Clevel, OH
6Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH

4753 Safety and Efficacy of Once Weekly Subcutaneous Bortezomib in Advanced Stage AL Amyloidosis
Poster Session: 653. Myeloma: Therapy, excluding Transplantation: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Naresh Bumma, MD1*, Frederic J. Reu, MD2, Christy Samaras, DO2, Hien K. Duong, MD2, Mitchell R. Smith, MD, PhD2 and Jason Valent, MD2*
1Internal Medicine, Cleveland Clinic, Cleveland, OH
2Taussig Cancer Institute, Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, OH

4760 Targeting HDAC6 Is a Novel Approach to Augment the Therapeutic Benefit of Bromodomain Inhibition in Multiple Myeloma
Poster Session: 653. Myeloma: Therapy, excluding Transplantation: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Jennifer S. Carew, PhD1, Claudia M. Espitia, MS2*, Weiguo Zhao, MS2*, Kevin R. Kelly, MD3* and Steffan T. Nawrocki, Ph.D.2
1Department of Translational Hematology & Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
2CTRC Institute for Drug Development, University of Texas Health Science Center at San Antonio, San Antonio, TX
3Noms Comprehensive Cancer Center, University of Southern California, Los Angeles, CA

4801 Viral Insertion Safety in Patients with Glioblastoma Who Received a Novel Lentiviral MGMT-P140K Gene Therapy to Protect Bone Marrow from Chemotherapy: No Dominant Clonal Evolution Observed with Chemo-Selection
Poster Session: 801. Gene Therapy and Transfer: Poster III
Monday, December 8, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center)
Hua Fung1*, Andrew E Sloan1,2*, Jane Reese1*, Basem M. William, MD3,4, Karen Langas1*, Lisa R Rogers1*, Heather Embree5*, Hillard M. Lazarus2, Donna Kane2*, Boro Dropulic5 and Stanton L. Gerson2
1Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
2University Hospitals Seidman Cancer Center, Cleveland, OH
3Hematology and Oncology, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH
4Medicine - Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH
5Lentigen Technology Inc, Gaithersburg, MD